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ABSTRACT
This thesis is divided into five chapters. Chapter one 
provides a brief outline of the history of $-lactams. New 
developments in screening methodology and current understanding 
of the mode of action of 8-lactams are presented. A section 
on the biosynthesis of 8-lactams is included.
Our aim in this project was to develop a system for 
investigation of the biosynthetic pathway leading to Thienamycin, 
the first representative of a unique class of 8-lactams - the 
carbapeneras. It was recognised that due to the intrinsic 
instability of Thienamycin and non availability of a high 
yielding strain, that the essential preliminaries of development 
of a fermentation and convenient assay techniques would form 
a major part of the effort.
Chapter two describes the fermentation studies carried 
out with Streptomyces cattleya and includes brief coverage 
of regulatory controls that may influence antibiotic 
production in Streptomyces. Possible causes of the significant 
degree of variability in 8-lactam production, observed in 
S. cattleya fermentation are also presented.
Chapter three covers the development of analytical 
techniques used in the detection and identification of 
Thienamycin and co-produced 8-lactams. An attempt was made 
to discriminate between co-produced carbapenems on the basis 
of their structure-activity relationship. The major 8-lactam 
product of fermentation was identified as Thienamycin.
The experimental section is to be found in chapter four.
Chapter five reviews the results of our studies with 
S. cattleya, the main emphasis of the work being directed 
to optimising the fermentation and assay systems. Current 
understanding of the biosynthesis of carbapenems in 
Streptomyces sp. with particular attention to production of 
Thienamycin by S. cattleya, together with recent developments 
in the field of biosynthesis, such as protoplast and genetic 
engineering techniques are also discussed.
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CHAPTER ONE 
INTRODUCTION
1. 1 INTRODUCTION
Chapter one provides a brief outline of the history of 
3-lactams. New developments in screening methology, and 
current understanding of the mode of action of 3-lactams are 
presented. A section on the biosynthesis of 3-lactams includes, 
recent developments in the field of classical 3-lactams, and 
initial studies for the non-classical groups. Our aims and 
objectives are set out in a final section.
Naturally occuring 3-lactam structures have generally been 
defined and classified using trivial nomenclature. More 
recently a system based on a defined parent 3-lactam skeleton 
( or 'nucleus' ) has been available. Penicillins and 
cephalosporins being derived from penam and cephem nuclei 
respectively, while other 3-lactams are based on clavam, 
carbapenem, penem, oxacephem, and monobactam ring systems, 
see Figure (1.1). Predominantly trivial nomenclature will be 
used throughout this thesis due to the cumbersome nature of 
wholly systematic nomenclature for 3-Lactam structures. 
Penicillins, cephalosporins and cephamycins are referred to 
as classical 3-lactams, and the newer groups as nonclassical 
3-1 actams.
Figure (1.2) gives the structures for 3-lactam antibiotics 
referred to in the text, section (1.2). ( See pages 8-11 ).
Figure (1.3) lists structures for the carbapenem class 
of 3-lactam ( not exhaustive ). ( See pages 12-16 ).
(6)
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1.2 3-LACTAM ANTIBIOTICS - A SHORT HISTORY
1.2.1 The Advent of Penicillin
More than half a century has elapsed since Alexander
Fleming discovered penicillin while working at St. Mary's
(34)Hospital, London, . Three years after his initial
discovery Raistrick and co-workers published a study of
penicillin which gave details of the solvent extraction of
(35)the antibiotic and also noted its instability,
Subsequently Howard Florey, Ernst B. Chain, and their
colleagues at Oxford University demonstrated the potential of
(36)penicillin as a therapeutic agent, , Table (1.1). The
chemotherapy of bacterial infections was to change, drastically
as further developments in this field gave rise to a large
( and ever increasing ) family of antibiotics. It is not
possible in this brief review, to give credit to the many
great scientists who have made valuable contributions in this
area, more comprehensive coverage is available elsewhere, 
(36,37,38,39)
Penicillin ( Pen. G ) first became available for clinical
use in the early 1940's, , initially many common
infections yielded to therapy. By 1945 the 8-lactam structure
proposed for penicillin by Abraham, Baker and Chain, had been
( 38)confirmed by X-ray crystallographic analysis, . Also
it had been demonstrated that penicillins with different non­
polar side chains could be derived by the addition of the 
appropriate monosubstituted acetic acid to PeniclIlium notatum 
fermentations. Discovery of the relative acid stability of
Phenoxymethylpenicillin ( Pen. V ) in 1954, provided the first
(38)
penicillin suitable for oral administration,
(17)
TABLE (1.1)
SUMMARY OF SOME OF THE ACHIEVEMENTS OF H. FLOREY, E. B. CHAIN 
AND CO-WORKERS, IN THE DEVELOPMENT OF PENICILLIN AS A 
THERAPEUTIC AGENT, (36^
1) Cultivation of Penicillin notatinn, isolation and 
concentration of penicillin by solvent extraction 
and freeze drying.
2) Determination of the range of sensitive bacteria, 
found that penicillin was active in the presence 
of body fluids.
3) Established penicillin as a systematic chemo­
therapeutic agent using animal experiments.
4) Accumlated sufficient penicillin to administer to 
first patents in various Oxford hospitals.
5) Made the first important steps in the elucidation 
of the chemical structure of penicillin.
6 ) Discovered an enzyme ( ' penicillinase 1 ) as one 
of the main causes of instability of penicillin.
(18)
The clinical limitations of the early penicillins had 
become apparent by the mid 1950's. Antibacterial activity 
was primarily directed at Gram positive cocci, in addition 
the incidence of penicillin resistant infections was now 
significant. Strains of Staphylococci capable of producing an
i »
enzyme ( penicillinase ) which hydrolysed the 3-Lactam ring 
of penicillin, were frequently isolated. However interesting 
new developments were to ensure that the penicillin story 
continued.
1.2.2 Semisynthetic Penicillins and Cephalosporins
1.2.2.1 Semisynthetic Penicillins
An event which was to change the course of 3“lactam 
research, occurred at Beecham Laboratories in 1956. 
Investigations revealed that the parent substance of penicillin, 
6-aminopenicillanic acid (6APA) could be obtained from certain 
fermentations ( an observation that had been made in Japan
/ 38 \
some years earlier ), . Later when 6APA became available
in bulk quantities, by enzymic or chemical hydrolysis of the
natural penicillin, the potential of derivatives prepared by
(41)
chemical acylation of the nucleus was explored,
During this period attempts were made to solve a number
of problems by modification of the penicillin ' nucleus '.
Firstly stabilisation of the molecule to staphylococcal
penicillinase, secondly expansion of the antibacterial
spectrum to include Gram negatives, and thirdly development
(39)
of acid stable orally absorbable penicillin derivatives,
A vast range of semisynthetic penicillins were now 
possible. The development of Methicillin, a penicillin stable
(19)
to staphylococcal penicillinase, effectively solved the 
problem of penicillin resistant staphylococcal infections.
In 1961 Ampicillin became the first orally administered broad 
spectrum penicillin. Ampicillin, although susceptible to the 
staphylococcal penicillinase, was found to be considerably 
more active than Benzylpenicillin ( Pen. G ) against many Gram 
negative organisms.
1.2.2.2 Semisynthetic Cephalosporins
Natural occurrence of a second class of 3-lactam, the
cephalosporins, was first recognised in 1955. Cephalosporin C
was detected as a trace contaminant during isolation and
purification of Penicillin N from the fungus Cephalosporium 
( 42 )acremonium, . Discovery of a chemical method for the
removal of the a-aminoadipyl side chain of Cephalosporin C,
by workers at Lilly in 1962 , and the production of 7-amino
cephalosporanic acid (7ACA) in quantity, paved the way for
exploration of the potentialities of the cephalosporin ring 
<38)system,
Production of semisynthetic cephalosporins was accomplished
by acylation of the amino group and modification of the C-3
substituent of 7ACA. Cephalosporins generated considerable
clinical interest, due to their greater intrinsic resistance
to enzymic degradation, and broader spectrum of antimicrobial
(43)activity, . Cephalothin became available in the early
19 60's, as the first semisynthetic cephalosporin. Cephalothin
satisfied two goals in 3-lactam research, being very
resistant to staphylococcal penicillinase, and demonstrating
(39)activity against common Gram negative infections,
(20)
Cephalexin provided the first semisynthetic cephalosporin 
suitable for oral administration.
By the late 1960's, changing patterns of infection and
the increasing frequency of isolation of opportunistic pathogens,
focussed attention on the growing problem of resistance in
Gram negative bacteria. An important factor was the ability
of many resistant organisms to produce a cell bound 3-
(38)lactamase, . It was recognised that many 3-lactamases
with different substrate profiles existed, and while some 
were chromosomally determined others were mediated by plasmids 
which could readily be transferred from one organism to 
another. Additionally the incidence of infections caused by 
bacterial species, such as Pseudomonas, Serratia and Entero- 
bacter, not amenable to 3-lactam antibiotics was now significant.
Research efforts eventually achieved success with the 
development of new antipseudomonal penicillins and cephalosporins, 
new types of 3-lactamase resistant cephalosporin, and non- 
classical 3-lactam antibiotics.
1.2.3 Expanded Spectrum and Antipseudomonal Penicillins and 
Ceph alosporin s
Substitution of the a-amino group of Ampicillin with a 
carboxyl group, resulted in a penicillin with wide ranging 
antibacterial activity, that included some strains of 
Ps. aeruginosa. Carbenicillin ( a-carboxypenicillin ) was 
introduced in 19 6 7 as the first parenteral antipseudomonal 
penicillin. Many similar a-acidic group substitutions were 
performed, and resulted for example in Cefsulodin in the 
cephalosporin series.
(21)
Modification of the a-amino group of the penicillin or
cephalosporin molecule, by acylation with, aliphatic, aromatic
or heteroaromatic carboxylic acids gave derivatives with
expanded spectrum and especially increased activity against
Ps. aeruginosa. This approach led to the development of
3-Lactam antibiotics such as Azlocillin, Piperacillin, and 
(39)Cefoperazone,
1.2.4. New Cephalosporins
Since 19 70 new types of cephalosporin have appeared, which
show increased stability to a number of 3-lactamase, when
(39)compared with their predecessors,
The cephamycins ( 7a-methoxycephalosporins ) were discovered
as products of Streptomyces, by Nagarajan and co-workers in 
(44)1971, . The 7a-methoxy substitutent was found to confer
resistance against 3-lactam hydrolysis by 3-lactamase. There 
resulted a number of synthetic cephamycin derivatives, 
prepared by chemical methoxylation of the 3-lactam nucleus. 
Cefoxitin became clinically available in 19 72 and demonstrated 
good activity against Gram negatives.
In addition a number of cephalosporin derivatives, 
without the 7a-methoxyl substituent demonstrated considerable 
stability to 3-lactamase. A common structural feature was 
the presence of a 7a-methoxyimino side chain, consequently 
this group of derivatives became known as the oxime 
cephalosporins, examples are Cefuroxime, and Cefotaxime.
1.2.5 N on -Classica1 3-Lactams
1.2.5.1 Chemical Modification of Penicillin and Cephalosporin 
Nuclei
(22)
During the early 19 70's Streptomyces species capable
(44 45 46)of producing 3-lactam antibiotics were discovered, ' '
In addition to classical 3“iactam antibiotics, naturally
occurring compounds with novel 3-lactam nuclei were isolated
( see section 1.2.5.2 ). This discovery, together with the
clinical success of the semisynthetic cephamycin derivatives
may have prompted the re-examination of the concept of
( 47 48nuclear modification that occurred in the late 1970's * '
49 ,50)
Moxalactam ( lately known as Latamoxef ) was developed
for clinical use in 1978. An oxacephem derivative, chemically
transformed from penicillin, with a 7a*-methoxy substituent , it
was shown to be more active than the cephalosoorin analogue.
(3)and also stable to a wide range of 3-lactamase types,
1.2.5.2 Novel 3-Lactam Compounds
Further screening of Streptomyces sp., following discovery
(44 45 46 )of the cephamycins in 19 71, ' ' , has revealed many
new and potentially useful compounds, with novel 3-lactam
structures. Section 1.2.6 deals with the changes in screening
procedure that have brought this about. Discoveries include,
( 51 )Clavulanic acid, , whose structure is based on the
( C O  C "3 \
clavam ' nucleus ', Olivanic acids/Epithienamycins, ' '
together with other 3-lactams of the carbapenem class, ^16,25)
including the highly active 3-lactamase resistant carbapenem
Thienamycin, ^1°  ^f and a family of monocyclic 3-lactams, the
(4 )Nocardicins,
A recent development was the discovery of 3-lactam
(54 )compounds produced by bacteria, . Independantly workers
in Japan and workers at Squibb discovered a new class of
(23)
3-lactam antibiotic, termed the monobactams, produced by 
strains of Gram negative bacteria, (®*55)^ Sulfazecin, 
the most commonly found structure was initially isolated
/ o \
from Pseudomonas acidophila, . The monocyclic nature 
of this class of $-lactam changed considerably the definition 
of structural parameters required for antimicrobial activity.
In addition to the monobactam series, (56,57)  ^bacteria
/ c o \
have been shown to produce, a simple carbapenem nucleus, ,
a number of cephalosporins, (59,60) ^ a group of 3-lactam
related compounds the 3-lactones , (9/61)^ New g-iactam 
structures continue to be discovered, .
1.2.6. Developments in Screening Techniques for 3—Lactam 
Antibiotics
The abundant discovery of new and novel 3-lactam 
containing molecules in recent years may be attributed to 
several factors. Significant among these was the renewed 
enthusiasm on the part of researchers, following discovery of 
cephamycins as products of Streptomyces, (-44,45 ,46)^  Also 
introduction of new isolation techniques, and novel ' mode 
of action 1 screens, directed toward the discovery of
antibiotic producing organisms have played an important
-> (63)role,
A variety of approaches in screening methology have been
adopted, (53,64)  ^ g-Lactam antibiotics can be detected in
screens which look for inhibitors of peptidoglycan synthesis, 
(63) The cephamycins were detected using a screen developed
to look for agents producing morphological changes in
(44)
sensitive bacteria, . Thienamycin, and subsequently
the Epithienamycins, were discovered in the course of screening
(24)
soil microorganisms for production of inhibitors of 
peptidoglycan synthesis in Gram positive and Gram negative 
bacteria, (10,52,65 )  ^ t^e preC£se details of the method
used have not been published.
The observation that 3-lactam antibiotics could act as 
3-lactamase inhibitors prompted the screening of micro­
organisms for naturally occuring inhibitors of this enzyme. 
Clavulanic acid, , and the Olivanic acids, (53,65) ^
(67 6 8 )together with other 3-lactams of the carbapenem class, ' ,
were discovered using this strategy.
3-Iactam supersensitive bacterial mutants have been used
very successfully in directed screening procedures. A series
of monocyclic 3-lactams, the Nocardicins were discovered using
(4 )a supersensitive mutant of Escherichia coliy . Kitano
et al reported the production of penicillins and cephalosporins
by fungal strains not previously associated with the
production of these compounds, using a supersensitive mutant
( 69 )of Ps. aeruginosa, . Bacterial mutants have also been
used to detect novel 3-1 actam antibiotics of bacterial origin,
(S) #
One of the latest developments in this field was the use 
of 3-lactamase induction screens, (®^ ) . 3-Lactam antibiotics 
were found to induce 3-lactamase production in certain strains 
of Gram positive and Gram negative bacteria, (64,70)^ A 
high degree of specificity was demonstrated for 3-lactam 
containing molecules using this methodology, false positives 
were obtained with a group of related compounds, the 
3-lactones, (54)^
Introduction of novel strategies for the detection of 
6-lactam containing molecules has led to the discovery of
(25)
new 3-lactam antibiotics, novel structural classes, and to
the detection of antibiotic production in microorganisms not
previously associated with the synthesis of these compounds.
Success in the future will depend on the sensitivity and
specificity of the screening procedures available. New
developments continue to be reported, including the use of
(71 )isolated enzymes of peptidoglycan synthesis, , and
(72)
screens to detect the triggering of autolytic enzymes,
1.2.7 Future Prospects
Further growth in the field of 3-lactam antibiotics seems 
assured, due to their outstanding clinical value, coupled 
with limitations in the face of changing patterns of infectious 
disease and bacterial resistance/providing a powerful incentive 
to continued research.
Developments in screening techniques may yet reveal new 
3-lactam structures with novel biological properties. The 
search for new 3”lactams with novel activity against specific 
pathogens is likely to continue, with the trend towards 
' custom ' antibiotics as opposed to those with wide ranging 
broad spectrum activity. Future generations of 3-Lactam 
antibiotics may include compounds demonstrating high activity 
against selected organisms ( or selected target sites ), with 
the use of synergistic mixtures becoming more significant.
Such a strategy may enhance the chance of successfully 
treating infectious disease. A current example is the co­
administration of the 3-lactamase inhibitor Clavulanic acid
together with the otherwise 3-lactamase susceptible penicillin
TM ( 41 )Amoxycillin, ( Augmentin ),
Although total chemical synthesis of many 3-lactam
(26)
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( 73 )antibiotics and their nuclear analogues has been achieved, '
economic considerations have favoured a semisynthetic approach
from natural products. A recent exception to this was the
( 74 )total chemical synthesis of the carbapenem Thienaraycin, ,
( N-Formimidoyl thienamycin in combination with renal
dipeptidase inhibitor, Cilastatin, was marketed in early
19 86 under the brand name Primaxin ). The monocyclic nature
of the monobactams, has made this class of 8-lactam an ideal
( 75 )subject for chemical synthesis, . Azthreonam is an
example of a totally synthetic novel structure, with improved 
properties over naturally occurring compounds, and as such may 
be an indicator of future trends.
1. 3 MODE OF ACTION OF 8-LACTAM ANTIBIOTICS
Interaction between 8-lactam antibiotics and bacteria
( 76 )is a very complex multilevel phenomenon, . Factors
such as the penetration of 8-lactams into the bacterial cell,
(77)
and the significance of 8-lactamase are not discussed here,
1.3.1 Target of 8-Lactam Antibiotics
The 8 “lactam antibiotics presented a group of ideal 
chemotherapeutic agents, due to their high selective toxicity 
for bacteria, which led to speculation as to their mode of 
action. Important clues were provided by, the localisation 
of radioactively labelled penicillin in the bacterial cell, 
and the morphological and biochemical effects of penicillin,
I H C 7P \
' . It was observed that the sensitivity of bacteria
to 8-lactams was paralleled by the presence of a rigid cell 
wall.
(28)
Following elucidation of the structure and biosynthesis
(78 )of the peptidoglycan cell wall, /it was demonstrated
that one of the terminal steps in cell wall biosynthesis
was the penicillin sensitive reaction, (79,80,81 rp^ -g
final cross linking reaction, catalysed by peptidoglycan
transpeptidase, was found to be penicillin sensitive, see
Figure (1.5). Recent reviews of the structure and biosynthesis
/ 82 83)of the bacterial cell wall are available, ' ,
Figure (1 .6 ) summarises the events of cell wall biosynthesis.
Tipper and Strominger, ( ^  proposed that penicillin
inactivated peptidoglycan transpeptidase by acting as a 
structural analogue of the dipeptide terminus of the nascent 
pentapeptide chain, see Figures (1.5) and (1.6). It was
further suggested that 6-lactam antibiotics were active site
a.  ^ i . (76 ,80,84 )directed acylatmg agents, capable of
acylating the transpeptidase and thereby inhibiting its
activity. Other enzymes concerned with the cross linking
step in peptidoglycan biosynthesis, namely D-ala carboxy-
peptidase and endopeptidase, were also recognised to be
( 7 P )penicillin sensitive, .
1.3.2 Penicillin Binding Proteins (P.B.P's)
Demonstration of the ability of penicillin to bind
covalently to the enzymes that it inhibited, provided a means
of detecting the penicillin sensitive enzymes as penicillin
(85 )binding proteins, . The situation, with regard to mode
of action of 6-lactams, was further complicated when it was
shown that bacterial plasma membranes contained groups of
( 86 )proteins that bound penicillin specifically,
Existence of multiple P.B.P's suggesting the possibility of
(29)
FIGURE (1.5)
DIAGRAMATIC REPRESENTATION OF (A) CROSS-LINKED STRUCTURE OF
PEPTIDOGLYCAN AND (B) REACTION INHIBITED BY PENICILLIN 
(36 ,87,88)
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FIGURE (1.6)
SUMMARY OF EVENTS OF CELL WALL BIOSYNTHESIS IN BACTERIA
(36,87,88)
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FIGURE (1.6) Continued
KEY
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UDP - uridine diphosphate 
PEP - Phosphoenol pyruvate 
Pi - inorganic phosphate 
Pentapeptide - as Figure (1.5)
- Reaction inhibited by penicillin
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multiple targets for penicillin action.
However the role of the P.B.P1s in peptidoglycan 
biosynthesis remains unclear, different subclasses of P.B.P.
have been associated with cell elongation, septum formation,
. ,, , , ,, . . (76,78,85,89,90)control of cell shape and cell division, ' _ ’ '
Also experiments with model substrates have revealed that
at least some P.B.P.'s can catalyse carboxypeptidase,
(76)endopeptidase and transpeptidase reactions, . Different
8-lactam antibiotics demonstrate selective affinity for
(78)different subsets of P.B.P.'s, , indicating how their
bactericidal effects may be mediated.
1.3.3 Physiological Effect of 8-Lactam Antibiotics
The lethal effect of 8-lactam antibiotics on bacteria, 
would appear to be more complicated than the simple inactivation 
of one or more essential enzymes. Existence of a number 
of penicillin sensitive proteins ( carboxypeptidase, trans­
peptidase, P.B.P.'s ), with distinct physiological roles, 
and the highly selective affinities demonstrated by different 
8-lactams, suggest that there may be more than one mechanism
for cell inhibition. Thus the single target-unbalanced 
(76)growth model, , in which penicillin inhibits a target
enzyme, which then leads to disturbances in peptidoglycan 
synthesis and ultimately to cell death by uncontrolled lysis, 
may be an oversimplification of the true situation.
The pathway from inhibited enzyme(s) to inhibited
bacterial cell may vary considerably, and is likely to be
highly complex depending on the particular 8-lactam, the
(91)bacterial species, and the environmental conditions,
(33)
Contributing factors to this complexity are the number of 
possible targets for 8-lactam antibiotics, and the
(76)mechanistically different effectsthat may result, .
8-Lactam antibiotics can cause, inhibition of cell wall 
assembly and therefore growth ( the primary response ) j loss 
of viability, and cell lysis.
Autolysins ( peptidoglycan hydrolase ) have an important
role to play in the secondary response of cell lysis, as is
(92 93)shown by the phenomenon of ' tolerance 1, ' . A
primarily bacteriostatic response to penicillin, being obtained
with organisms whose autolytic system was defective, or had
been compromised by the use of specific inhibitors of
peptidoglycan hydrolase. The bactericidal and lytic effects
observed as the secondary response, may well involve factors
other than the primary targets of 8-lactams, and do not appear
to be an automatic consequence of the inhibition of cell
(76 91 93)wall synthesis, ' ' Recently it has been shown that
exposure of cells to 8-lactam antibiotics can lead to
(9 4)
1 triggering 1 of the autolytic system, , and to a
decrease in the degree of O-acetylation of the peptidoglycan
(9 4)polysaccharide moiety, , the significance of these
observations is not yet clearly understood.
The mechanism of action of 8”lactam antibiotics is a 
complex phenomenon, involving the interplay of a number of 
different factors, including inhibition of the final cross 
linking step, and other more subtle disturbances of peptido­
glycan synthesis.
(34)
1.4 BIOSYNTHESIS OF g-LACTAM ANTIBIOTICS
1.4.1 Classical g-Lactams
Studies of the chemistry of g-lactam containing molecules 
have been extensive, in addition investigation into the
biosynthesis of this group of antibiotics have proved 
fruitful. Many features of the biosynthesis of 8-lactams 
have been clarified in recent years, however a number of
mechanistic steps remain obscure and are currently under
on, <95>. E>
(43,95,96,97)
(95)investigati xcellent reviews of this field are
available,
A composite picture of penicillin cephalosporin and 
cephamycin biosynthesis,compiled from data from many micro­
organisms, is shown in Figure (1.7), .
1.4.1.1 Whole Cell Studies
Originally, possible biosynthetic precursors were
suggested on the basis of the known chemical structure of
(43)penicillins and cephalosporins, . Early studies involved
addition of potential precursors to the fermentation, and
(41 96)noting the effect on antibiotic production, '
Feeding studies with isotopically labelled cysteine and valine,
demonstrated intact incorporation into penicillins and
cephalosporins, thus confirming their role as precursors,
(95 96)' . There then followed a search for potential peptide
precursors of g-lactam antibiotics. This lead to discovery 
of the tripeptide 6-( L-a-aminoadipy1 )-L-cysteinyl-D-valine, 
(LLD-ACV), by Arnstein and co-workers, (97,98)^ LLD-ACV 
was presumed to be the precursor of penicillins and 
cephalosporins although direct demonstration of its role was 
not possible using whole cells due to permeability restrictions
(35)
COMPOSITE PATHWAY OF PENICILLIN, CEPHALOSPORIN AND CEPHAMYCIN 
BIOSYNTHESIS IN FUNGI AND ACTINOMYCETES (96)
L-a-aminoadipate (L-AAA)
L-cysteine (L-CYS)
'L-AAA-L-CYS
L-valine (L-VAL)
L-AAA-L-CYS-D-VAL (LLD-ACV tripeptide)Phenylacetate
Phenylacetyl- 
CoA
Isopenicillin N
Penicillin N
Benzylpenicillin
Deacetoxycephalosporin C 
Oor
acetate acetylCoA
Cephalosporin C
Deacetylcephalosporin C
V
 Carbamoyl 
phosphate
0 - c arb amoy lde ace t y 1 
Cephalosporin CO.
S-adenosylmethionine,
7a-methoxy Cephalosporin C Cephamycin C
7amethoxy -svcarbamoyl phosphate
acetate deacetyl Cephalosporin C
Cephamycin B
i
Cephamycin A
N.B. no single microorganism can carry out all reactions 
illustrated
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(43 99)imposed by the intact cell envelope, '
However whole cell studies using isotopic and chiral
labelling of precursor have provided many insights into the
(95)reactions of 3-lactam biosynthesis, . For example
experiments with valine possessing labelled methyl groups,
revealed that the S-C bond of penicillin was formed with
(41 96)retention of configuration at the carbon atom, '
Isotopic labelling of precursors established that L-a-amino 
adipic acid, L-cysteine and L-valine were incorporated intact 
into LLD-ACV tripeptide.
1.4.1.2 Cell Free Systems
Conclusive evidence of a direct role for LLD-ACV in 
penicillin biosynthesis was provided a decade ago, with the 
conversion of the tripeptide into isopenicillin N, using a 
cell free ( lysed protoplast ) system of Cephalosporium 
acremonium, (^ 00, # The presumed role of isopenicillin N
as a precursor of cephalosporins was also confirmed in this 
way, (-^ 02). Subsequently major advances in understanding of 
the biosynthetic pathway of penicillins, cephalosporins and 
cephamycins were made, using various cell free systems, (. once 
the importance of appropriate cofactors was appreciated ), 
together with elegant radiolabelling studies, (-43,95,96,103, 
104,105)  ^ Recently it was confirmed that the LLD-ACV 
tripeptide itself undergoes intact incorporation, although the 
mechanism of cyclisation remains to be determined, (-^ 06) ^
A more detailed summary of the accepted biosynthetic
sequence leading to the classical 3-lactams is given elsewhere 
(45 95 96 97)' ' ' . It should be noted that no single micro­
organism can carry out all the conversions illustrated, .
( See Figure (1.7) )
(37)
1.4.1.3 Studies of the Biosynthetic Enzymes
Although progress has been rapid in determining the 
biosynthetic pathway of the classical 3-lactams, the mechanisms 
by which the individual reactions occur are not well understood. 
Currently interest is focussed on transformations at the 
enzyme level. The biosynthetic enzymes responsible for 
elaboration of penicillins, cephalosporins and cephamycins 
have been at least partially elucidated, C43,96,107,108,109)^
Baldwin et a l  ^ 1 ° ) r have recently succeeded in producing 
a new type of penicillin by enzymic synthesis, using purified 
isopenicillin N synthetase (IPNS) and a novel tripeptide 
precursor. It was observed that the requirement for the 
valine moiety was not absolute and could be replaced by 
O-methylallothreonine or isoleucine, leading to the formation 
of novel penam structures. Baldwin et al indicated that their 
findings are in agreement with the currently favoured free 
radical mechanism of cyclisation, involving an enzyme bound 
monocyclic intermediate, .
The molecular genetics of antibiotic biosynthesis are
i u • u * (107,111,112,113) ... ..also being approached, ' , with the recent
(114 115)cloning of biosynthetic genes, ' , and attempts at
sequencing, most notably that for the IPNS gene.
1.4.2 Non Classical 3-Lactams
Determination of the biosynthetic pathway leading to 
novel 3-lactam classes ( clavam, carbapenem and monobactam 
compounds ), is very much in its infancy. Despite their 
structural relationship with classical 3-lactams, a distinct 
biosynthetic origin seems likely from the preliminary studies
(38)
FIGURE (1.8)
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so far carried out. Although the LLD-ACV tripeptide does
(95)
not appear to be involved, , the possibility of a common
ring closure mechanism ( using common enzymes ? ) cannot be 
excluded.
1.4.2.1 Clavulanic Acid
Biosynthetic studies using (^ C) and C c^) labelled
(95 ,96 ,116) . .. . , . . , . ..precursors, , have attempted to identify the
metabolic origin of the carbon skeleton of the potent
(51)
irreversible 8-lactamase inhibitor, Clavulanic acid,
It was suggested that carbons 5,6 and 7 of the 8-lactam ring
could come from glycerol or a late intermediate of the TCA
(6)cycle, , and that carbons 9,8 ,2,3, and 10 of the oxazolidine 
ring could be derived from glutamate, , see Figure (1.8).
However more recent studies indicate that ornithine may be 
the precursor of the oxazolidine ring, .
1.4.2.2 The Monobactams
The monobactams are a group of novel monocyclic 8-lactams
of bacterial origin, (®*55)^ Figure (1.2) gives the structure
of sulfazecin the most commonly produced monobactam. Studies
indicate that serine is the source of the carbon atoms of the
8-lactam ring, with methionine the source of the methoxyl 
(7)substituent, , inorganic sulphate providing the 
sulphamate group, (118).
1.4.2.3 The Nocardicins
The nocardicins are a series of novel monocyclic 8-lactams
(4)produced by Nocardia unifOrmis subspecies tsuyamensis,
A biosynthetic pathway has been postulated on the basis of
14
studies using ( CJ labelled amino acids, and the stimulatory
(40)
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effect of, L-tyrosine, p-hydroxyphenyl pyruvic acid, DL 
p-hydroxyphenyl glycine, on antibiotic production, (^,96) 
see Figure (1.9).
1.4.2.4 The Carbapenems
At the commencement of this project few biosynthetic
studies had been carried out for this 3-lactam class. It
had been reported that glutamate was a precursor for the 5-
membered ring of Thienamycin, the 3-lactam carbons being
(95 119)supplied by acetate, ' , see Figure (5.1), chapter five.
Coverage of the situation currently is given in chapter five.
1.5 Aim of Work
Our aim in this work was to develop a system for 
investigation of the biosynthetic pathway to Thienamycin and 
related carbapenems, that would permit biosynthetic - 
mechanistic studies of the type carried out for penam and 
cephem 3-lactams. The systems we hoped to employ would 
include, the intact fermentation, resuspended mycelium, and 
resuspended protoplasts. Extensive use would be made of 
radiolabelled precursors and autoradiographic techniques.
It was recognised at the outset, due to the intrinsic 
instability of Thienamycin and the non availability of a high 
yielding strain, that the essential preliminaries of developing 
a fermentation, and convenient assay techniques, isolation and 
purification procedures , would constitute a major part of 
the effort. In the event production of Thienamycin in 
adequate yield for isolation was not achieved, and the main 
emphasis of the work was directed to optimising the fermentation 
and assay systems.
(42)
CHAPTER TWO
FERMENTATION STUDIES AND CONTROL OF SECONDARY 
BIOSYNTHETIC PATHWAYS IN STREPTOMYCES CATTLEYA
(43)
2 - 1 INTRODUCTION
Chapter two covers the fermentation studies carried out 
with Streptomyces cattleya NRRL 805 7, and also includes a brief 
outline of factors influencing secondary metabolite production, 
with particular emphasis on the production of 8-lactam 
antibiotics by Streptomyces.
2.1.1 PRIMARY AND SECONDARY METABOLISM
Pathways of primary metabolism involve an interconnected 
series of enzyme mediated reactions which provide, biosynthetic 
intermediates, and energy, and convert biosynthetic precursors 
into essential macromolecules. Primary metabolites may be 
termed ' general ' metabolites, in that primary metabolism is 
essentially identical for all living organisms. In addition 
certain taxonomic groups are capable of synthesising secondary
or ' special 1 metabolites under specific nutritional
,... ( 120) conditions
Table (2.1) , lists characters used to describe primary and 
secondary metabolism.
2.2 REGULATION OF SECONDARY METABOLISM
The regulation of secondary metabolism is considered, 
primarily with respect to 8-lactam antibiotic production, 
although our understanding of the control mechanisms involved 
in secondary metabolism is limited, regulatory controls 
similar to those found in primary metabolism may operate.
2.2.1 Physiological Regulation
Physiological control of antibiotic production may be 
considered at three different levels
(44)
TABLE (2.1)
CHARACTERISTICS THAT MAY BE USED TO DIFFERENTIATE
BETWEEN PRIMARY AND SECONDARY METABOLISM
Primary metabolism
Essentially 
identical for all 
forms of life
Essential.for growth 
of the organism
Highly specific 
enzymes involved
Secondary metabolism
May be taxonomically 
restricted
Not necessary for 
vegetative growth 
( may have a survival 
function in nature )
Low enzyme specificity, 
often involves special 
synthetases
Metabolites rarely 
allowed to 
accumulate
Mixture of compounds 
of same type may 
accumulate- Proportion 
of each component in 
mixture influenced by 
environmental and genetic 
factors
-Often produced under 
specific nutritional 
conditions at low specific 
growth rates
-May possess biological 
activity which is expressed 
outside the producing 
organism
(45)
i) Control through environmental factors ( sources 
of carbon, nitrogen, phosphate, oxygen, metal 
ions ).
ii) Control through intermediary metabolism
( providing precursors and regulatory signals ).
iii) Control exerted at the level of the secondary 
biosynthetic pathway ( feedback regulation 
formation of autoregulators and autotoxic 
substances ).
A number of control mechanisms may operate at these 
(9 120 122)different levels ' ' . Regulatory controls, significant
in the production of 3“lactam antibiotics by Streptomyces sp., 
and in particular the production of carbapenems by S. cattleya 
are outlined here, Table (2.2).
2.2.1.1 Growth Rate Control
The microbial lifestyle places a premium on the capacity 
for rapid growth. Control mechanisms ensure growth takes 
priority over less urgent activities such as differentiation 
and secondary metabolism .
As early as 1965 Bu'lock observed biphasic patterns of
growth and antibiotic production, which appeared to indicate
an incompatibility between unlimited growth rates and
(122)secondary metabolism . Late expression of the synthesis
of antibiotics and other secondary metabolites is well known
. However, time separation between the growth phase
( ' trophophase 1 ) and the antibiotic production phase
(. ' idiophase ' ) is a function of the nutritional environment,
and not the type of molecule . in nutritionally deficient
media, growth and antibiotic production may occur simultaneously 
(122)
TABLE (2.2)
CONTROL SYSTEMS INVOLVED IN THE REGULATION OF
ANTIBIOTIC BIOSYNTHESIS AT THE PHYSIOLOGICAL LEVEL
a) Growth Rate Control
b) Carbon Metabolite Regulation
c) Nitrogen Metabolite Regulation
d) Phosphate Regulation
e) Metabolic Regulators
f) Regulation through Mineral Element 
Requirement
g) Regulation of Antibiotic Biosynthesis - 
Branched Pathways
(47)
In fermentation growth rate alone may appear to regulate 
secondary metabolism, antibiotic production occurring at low 
growth rate, irrespective of the type of nutrient limitation 
employed to produce the low growth rate. An example of this 
being the production of Cephamycin C by S. cattleya (126)  ^
Alternatively a specific nutrient deficiency may be necessary 
in addition to the low growth rate, for example production of 
Thienamycin by S. cattleya requires phosphate limited 
conditions for biosynthesis of this antibiotic to occur ( ^ 6 ) ^
Thus carbon, nitrogen and phosphate regulation may be involved 
in the growth rate control of antibiotic biosynthesis, .
2.2.1.2 Carbon Metabolite Regulation
Rapidly used carbon sources often exert regulatory effects,
fl2 2 )which can interfere with the biosynthesis of many antibiotics, '
Kahan et al indicated that, in S. cattleya fermentation, the
maximum rate of antibiotic synthesis occurred only after
substantial depletion of the major carbohydrate source,
glucose a regulatory mechanism of this type ensures
that the most easily metabolised nutrients are used for
rapid growth and that antibiotic production is suppressed d^O)^
Whether cyclic AMP has a role to play in carbon metabolite
(122)regulation of antibiotic synthesis remains unclear
2.2.1.3 Nitrogen Metabolite Regulation
Screening of nitrogen sources for inclusion in chemically 
defined media, used for antibiotic production, frequently 
results in selection of slowly metabolised amino acids, the 
use of which probably leads to nitrogen limited growth, .
That nitrogen regulation has a role to play in antibiotic
(127)
biosynthesis was demonstrated by Aharonowitz and Demain,
(48)
Ammonium was observed to interfere with cephalosporin formation 
in Streptomyces clavuligerus the ' ammonium effect ' 
appeared to operate at the level of the biosynthesis of the 
antibiotic synthetases, rather than their inhibition.
Glutamine synthetase is a key enzyme in nitrogen
metabolism, nitrogen regulation of antibiotic production may
(12 8)be mediated through the level or activity of this enzyme,
with S. clavuligerus high specific cephamycin production was
obtained under growth conditions that coincidentally led to
(12 9)high glutamine synthetase activity, . A similar situation
being found in the S. cattleya fermentation with regard to
f 12 9)
the antibiotic Thienamycin,
2.2.1.4 Phosphate Regulation
Phosphate may act as a crucial growth limiting nutrient 
in many antibiotic fermentations, (122,130}^  phosphate 
regulation of antibiotic production is widespread, affecting 
the synthesis of many diverse groups of antibiotics,
The range of environmental concentrations of phosphate 
tolerated during periods of vegetative growth are often much
greater than those which permit synthesis of secondary
. . . . . (131)metabolites,
It is possible that orthophosphate regulates the level
of another intra-cellular effector, that in turn controls
(132)
the expression of antibiotic biosynthesis, . Evidence
suggests that ATP may be involved, a high level of ATP
interfering with antibiotic synthesis. Time-course studies
have shown a rapid decrease in intracellular ATP just prior
(133)to the onset of antibiotic synthesis,
(49)
Thienamycin production in S. cattleya and
(133)cephalosporin production in S. clavu1 1gerus, , are
thought to be under phosphate regulation. Lilley et al
observed an increase in respiratory activity in response to
phosphate limitation in S. cattleya fermentation, (126) ^
was suggested that a change in glucose metabolism occurred
in the phosphate limited condition, that in turn promoted
Thienamycin synthesis. Kuenzi, d^4) pr 0p0se(^  that the
negative effect of high levels of phosphate on 6-lactam
formation in C. acremonium, was due to increased glucose
catabolism resulting in carbon source repression. The site
of carbon source repression in C. acremonium being the ring
(135)expansion enzyme.
Recent studies on the individual enzymes of antibiotic
biosynthesis in S. clavu li ge r us, indicate that the negative
effect of phosphate may be due to enzyme inhibition and/or
repression. Interestingly the ring expansion activity was
repressed when cells were grown at high phosphate concentrations 
(108)
2.2.1.5 Regulation through Mineral Element Requirement
The synthesis of secondary metabolites and structures 
of cellular differentiation often tolerate a much narrower 
range of environmental concentrations of specific trace 
metals, than does vegetative growth of the producer cells. 
Regulation of secondary metabolism by trace metals and 
inorganic phosphate has been summarised by E. D. Weinberg,
Biosynthesis of Thienamycin and related carbapenems, 
demonstrates an unusual requirement for trace amounts of 
cobalt, (52,53,65)^ This requirement being partially 
satisfied by addition of vitamin B-^ ( cyanocobalamin ), to
the fermentation medium during the growth phase, (136)^  
precise role(s) of cobalt in Thienamycin biosynthesis 
remains obscure.
Cobalt may regulate the biosynthesis of the antibiotic 
synthetases themselves, or may be responsible for the 
activation of preformed enzymes. Vegetative growth appears 
unaffected in media not supplemented with cobalt.
In S. cattleya fermentation glutamine synthetase activity
peaks and then rapidly declines prior to the onset of
(12 9)antibiotic biosynthesis, . Cobalt is known to alter the
(137)structural configuration of GS in Escherichia coli, ,
it is possible that cobalt fulfills this role in S. cattleya 
thereby regulating the activity of GS.
Cobalt may be required for formation of vitamin •
(1 3 8)and may function in enzyme conversions mediated by /
The conversion of homocysteine to methionine involves vitamin 
(139)B12 Methionine is known to act as a methyl group donor
in S. cattleya, carbons Cg and C^  of the hydroxyethyl side 
chain of Thienamycin originate from methionine, (136)^  Also 
other independent evidence suggests that cobalt may influence 
fermentative methylation in Streptomyces sp.
S. cattleya produces the non 3-lactam antibiotic, 
cyclopentenedione in fermentation, (-*-41)^ antibiotic is
believed to act by sequestration of metal ions (-*-42) f 
antibacterial activity can be reversed using a mineral salts 
solution, if the cyclopentenedione has a role in
regulation of antibiotic biosynthesis in S. cattleya, this 
could involve the sequestration of cobalt.
(51)
ch2oh
FIGURE (2.1) STRUCTURE OF THE CYCLOPENTENEDIONE ANTIBIOTIC 
PRODUCED BY S. CATTLEYA, (141)
2.2.1.6 Metabolic Regulators
Enzyme induction may be involved in controlling the
( 3 g 122)
biosynthesis of antibiotics, ' ' . Little is known of the
metabolic regulatory agents involved, as only a few substances
of this type have been studied in the chemically pure state
the stimulatory response may be the result of true enzyme
induction or in some cases to increased availability of 
(36)precursors, . Probably the most well known example is
the stimulation of Streptomycin biosynthesis in Streptomyces
(144)griseus by A-factor, . Processes of differentiation
and secondary metabolism may be connected, in that the same 
regulators may be involved in both activities.
In S. cattleya there is evidence that conditions which
promote secondary metabolism suppress sporulation, and 
(145)vice versa, . During the course of this work it was
observed that sub-cultures of S. cattleya which failed to 
express the ability to produce Thienamycin in fermentation, 
frequently sporulated poorly on solid media. Possibly 
secondary metabolism and sporulation in S. cattleya are
(52)
under common regulation.
2.2.1.7 Regulation of Antibiotic Biosynthesis in Branched 
Pathways
Control mechanisms operating in primary metabolism may 
be partly reflected in secondary metabolism, primary 
metabolites and intermediates act as precursors for secondary 
metabolism. In addition to feedback regulation of primary 
metabolism, they may take part in the regulation of 
synthesis of, and/or the activity of, enzymes involved in 
secondary metabolism, (12°/122)# Secondary metabolism may be 
regulated by a primary end product of a common branched 
pathway, the other branch of which leads to the antibiotic.
The antibiotic itself may inhibit the activity of the first 
dedicated enzyme of its biosynthetic pathway,d4^
2.2.2 Genetic Regulation
Streptomyces genetics have been excellently reviewed by
Chater and Hopwood, ^ 4^^/ other reviews deal more specifically
with the genetics of antibiotic production by Actinomyces 
(112,148,149)
Genetic regulation of antibiotic biosynthesis is a 
relatively unexplored field. With the increase in the 
versatility and scope of genetic analytical techniques (147)^  
and their application to antibiotic producing Actinomyces, 
hopefully this situation will alter. When considering the 
control of gene expression, in antibiotic biosynthesis two 
regulatory models have been proposed, ' ^ 2  ^;
Model 1 : A small molecule acts as a co-repressor or
inhibitor,repressing the formation of, or 
inhibiting the action of, the antibiotic
(53)
synthetases.
Model 2 : An inducer or activator must be synthesised by
the producing culture ( or added to it ! )
in order to initiate antibiotic biosynthesis.
Model 1 may fit the experimental data for carbon, nitrogen, or
phosphate, regulation. Model 2 could explain the effect of
/ Og \
A-factor on Streptomycin production in S. griseus,
2.2.2.1 Organisation of Antibiotic Biosynthetic Genes 
in Streptomyces
Clustering and partial clustering of related metabolic 
genes is common in the genus Streptomyces, Antibiotic
biosynthetic genes, that have been chromosomally mapped, 
tend to be located in the lower arc of the map, in
cases where several genes concerning the biosynthesis of the 
same antibiotic have been mapped, they are often assembled 
in clusters, suggesting co-ordinate regulation,
Okanishi proposed that plasmids could also be involved 
in antibiotic biosynthesis, Evidence that the
structural genes could be plasmid borne, was provided by the 
SCP 1 plasmid of St rep t omy ce s coeli color / SCP 1
carries the biosynthetic genes for production of the 
antibiotic Methylenomycin A. Plasmids may also be involved 
in regulation of antibiotic production, or resistance to the
antibiotic, rather than carrying the structural genes for
i . .. . (147)biosynthesis,
Umezawa suggested two possible modes of plasmid
/  "I C  Q  \
involvement in the production of secondary metabolites,
(54)
Firstly plasmids may be involved in the biosynthesis of 
products which promote synthesis of secondary metabolites. 
Secondly plasmids may be directly concerned with the 
biosynthesis of the enzymes which catalyse the synthesis of 
whole, or some molecular moieties of secondary metabolites.
2.3 FERMENTATION STUDIES WITH STREPTOMYCES CATTLEYA
2.3.1 Selection of Fermentation Media and Conditions
2.3.1.1 S. cattleya Fermentation in Complex Medium
Kahan et al indicated that a number of complex
media may be used for the fermentation of S. cattleya and
production of Thienamycin. Initially a range of media used
* * •. • . . ^ 4.. . 0 4 - 4 -  (128,133,145,154,for antibiotic production m  Streptomyces, '
, and several of the Kahan media, , were tested for
growth and antibiotic production. Fermentation was carried
out as a batch culture in shake flasks ( see Experimental ),
none of the chemically defined media supported significant
growth of S. cattleya, antibiotic production was not detected.
A complex medium, Kahan medium (E), was selected for use in
S. cattleya fermentation.
A growth curve for S. cattleya when grown on medium (E) 
is shown in Figure (2.3) , Figure (2.2) shows the growth 
curve for the S. cattleya seed inoculum. As expected for 
batch fermentation in nutritionally rich medium, high titres 
of antibiotic were achieved only after most of the cellular 
growth had occurred.
Although standard conditions were imposed, as far as 
possible , S. cattleya demonstrated some variability with
(55)
FIGURE (2.2)
A TYPICAL GROWTH CURVE S. CATTLEYA ; SEED INOCULUM (f-,)
SEED INOCULUM (f,) 
USED TO 
INOCULATE (f2) 
BETWEEN 35-42 HOURS 
! FERMENTATIONrH
U 40
oH 
® 20
10
TIME(t)/HOURS
£ 0.25 ml S. cattleya spore suspension ( approx. 1 x 10^ 
C.F.U./ML ) inoculated into 25 ml seed medium, in 250 ml 
conical flask. Flasks incubated 25°C, 220 rpm for up to 
3 days, (f^ ) then used as inoculum for (f2) fermentation
(56)
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FIGURE (2.3)
GROWTH CURVE FOR S. CATTLEYA (f2) FERMENTATION ON KAHAN 
MEDIUM (E)
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[j>.5 ml (f s e e d  inoculum, added to 25 ml Kahan medium (E) 
in 250 ml conical flask. Flasks incubated at 25°C, 220 rpm, 
biomass ( gram wet cells. L and pH recorded.
Activity in broth determined using P99 $-lactamase inhibition 
assay.
tgs (f2 ) mycelium from a number of flasks resuspended in 
defined medium and (f^ ) allowed to proceed, (f^ ) samples 
labelled as corresponding time in (f^) fermentation
Total activity in broth :
vs. s. aureus C. terigena
(f2 ) 94 hour, > 5yg/ml NFT = lOyg/ml NFT
(f3) 118 hour, = " " =  5  "
(M.I.C. broth dilution assay )
T.L.C. analysis of broth samples Figures (3.14), (3.15)
H.P.L.C. analysis of (f^) 94, (f^ ) 118 hour broth
Figures (3.17), (3.18) and (3.19)
(57)
respect to antibiotic production, antibiotic titre varying 
considerably from one run to the next. Titres equivalent 
to, 150 yg/ml N-Formimidoylthienamycin (NFT), as assayed by 
the Enterobacter cloacae P99 3-lactamase inhibition assay, 
or equivalent to 10 yg/ml NFT when assayed using Comamonas 
terigena or Staphylococcus aureus M.I.C. assays ( see 
Experimental ) could be obtained. Fermentation broth with 
P99 inhibitory activity equivalent to 50 yg/ml N-Formimidoyl 
thienamycin was assayed further to identify the different 
3“lactam antibiotics co-produced. ( chapter 3. )
2.3.1.2 S. cattleya Fermentation in Defined Medium
When fermentation of S. cattleya was carried out in 
medium (E), a foreshortened stationary phase, followed by a 
lytic phase was observed in some instances, see figure (2.4). 
Concommitantly very low or undetectable antibiotic titres 
were obtained ( < 0.156 yg/ml NFT, S. aureus M.I.C. assay ).
S. cattleya had previously demonstrated poor growth
on chemically defined media, therefore growth was initially
carried out on medium (E), the mycelium then being
resuspended in a defined medium. The medium used was a
( 133)modification of that of Aharonowitz and Demain v , 
supplemented with cobalt chloride ( 10 mg/ml ). Mycelium 
was resuspended at different stages during the fermentation, 
fermentation was then allowed to proceed in the defined 
system.
In the defined system, the biomass level stabilised 
after a period of biomass accretion, pH remained stable 
( between 6.5 - 7.0 ) for up to five days incubation,
(58)
FIGURE (2.4)
GROWTH CURVE FOR S. CATTLEYA (f2) FERMENTATION ON KAHAN 
MEDIUM (E) , LOSS OF BIOMASS (LYSIS), AND THE EFFECT OF 
RESUSPENSION IN DEFINED MEDIUM (f3), ON BIOMASS AND
FERMENTATION pH
MYCELIUM
RESUSPENDED
(ii
40 . ■ -16
30 - • -12
£ 20 .
H tn
10 -4
TIME (t)/HOURS
(i) (f ) Kahan Medium (E)
2
(ii) (f^ ) Defined Medium
  antibacterial activity vs S. aureus, determined using
M.I.C.broth dilution assay.
(f^ ) and (^ 2 ) carried out as described Figures (2.2) and
(2 .3) , mycelium resuspended in defined medium at t ^  hours
(f2) and (f^ ) allowed to proceed.
(f^ ) samples labelled as corresponding time in parent
fermentation
(f«) t-j^ c total activity broth = 12.5 yg/ml NFT 
6 1 vs S. aureus
(f2) t?6 „ „ , = 0.156 yg/ml NFT
(59)
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see Figure (2.4). Antibacterial activity equivalent to
12.5 yg/ml NFT ( S. aureus M.I.C. assay ), was detected in 
fermentation broth. Antibiotic titres in the defined system 
were 4 - 8 0  fold higher than those detected in the parent 
fermentation. In some instances antibiotic activity could 
be demonstrated in the defined system, when it was 
undetectable in the parent fermentation.
The defined system used here for S. cattleya fermentation 
may provide a relatively stable pH that is favourable for 
antibiotic production, it may allow the maintenance of 
biomass under nutritionally limited conditions that promote 
antibiotic biosynthesis. A similar system has recently been 
reported for S. cattleya fermentation, d ^ ) . , In addition to 
obtaining higher antibiotic titres, the defined system 
permitted use of the hydroxylamine extinguishable absorbance 
( X 299 nm ) of Thienamycin, to follow antibiotic production 
in fermentation broth and to obtain difference spectra,
( chapter 3 ).
2.3.2 Factors Affecting Antibiotic Productivity
During the course of this work difficulty was experienced 
in obtaining reproducible antibiotic titres in fermentation.
It is appropriate at this point to outline some of the 
possible causes of this observation, see Table (2.3).
Antibiotic production may be lost ( or exhibited ) as a 
result of :
2.3.2.1 Small Alterations in Fermentation Medium or Conditions
Antibiotic titre is often very sensitive to environmental 
variation, so that even if the underlying genetic determination
(60)
TABLE (2.3)
FACTORS THAT MAY AFFECT ANTIBIOTIC PRODUCTIVITY IN 
S. CATTLEYA FERMENTATION
a) Small alterations in fermentation medium 
or conditions.
b) Method of culture preservation.
c) Genetic factors
1) Mutation
2) Transposable elements
3) Insertions/deletions
4) Plasmid loss
5) Regulation of plasmid copy number.
(61)
is relatively simple, any inherent discontinuities may be 
obscured by environmentally induced variation, (1^8 )^
As S. cattleya fermentation was carried out in shake 
flasks, fermentation parameters could not be monitored 
or controlled ' in situ ' . However, measures were taken 
to eliminate any variation in medium composition.
Particular attention was paid to cleanliness of glassware, 
and over autoclaving of media. Medium constituents were 
obtained from the same batch where possible, freshly 
prepared batches of media were used throughout.
2.3.2.2 Method of Culture Preservation
Variation in culture viability and stability may be due
to the method of culture preservation used, and not to inherent
(156)
genetic instability, . Variations in culture maintenance
may affect culture viability, the ability to produce a
metabolite or the ability to respond reproducibly to an assay 
(156)
organism,
When S. cattleya was maintained by serial subculture on
agar slants, the ability to produce antibiotics and culture
viability were rapidly lost in a matter of weeks. Of the
other methods used ( preservation on sterile soil, lyophilisation )
maintenance of S. cattleya as a spore suspension in 50%
o (150,157)
glycerol at minus 20 C, , has been the most successful .
A viable culture was maintained for a period of six months 
using this method, however repeated freeze-thaw appeared to 
affect viability.
2.3.2.3 Genetic Factors
i) Mutation, involving straight forward DNA alterations in 
structural or regulatory genes.
(62)
ii) Transposable elements, transposition into a structural
or regulatory gene effecting loss of antibiotic biosynthesis.
iii) Insertions/deletions of genetic material.Baltz and
Stonesifer recently stated that the instability of
antibiotic production in Streptomyces fradiae could be 
due to a genetic rearrangement associated with the deletion 
or amplification of sequences linked to and possibly 
encompassing the Tylosin biosynthetic genes.
iv) Plasmid loss, loss of a plasmid carrying structural or
regulatory genes. Plasmid loss, possibly arising through 
inefficient segregation or partition of plasmids to 
daughter ce^ls at cell division, has been linked with loss 
of antibiotic production,
v ) Regulation of plasmid copy number. Plasmid copy number
varies considerably between different plasmids, but is
(15 9)fairly closely controlled for a particular plasmid,
If structural or regulatory genes were encoded on a 
plasmid, an increase in the copy number of that plasmid 
would increase the cell productivity for that gene product, 
and vice versa. Such a system would enable the organism 
to preserve the option of antibiotic production, and any 
adaptive advantage thereof, as no permanent loss of 
genetic information occurs.
With regard to antibiotic production in S. cattleya it 
is possible that the situation is obscured by the interplay 
of a number of different factors, at the environmental and 
the genetic level. The difficulties experienced may have 
arisen, not through any genetic instability, but through 
insufficient information about the particular environmental
(63)
conditions and regulatory controls that promote antibiotic 
biosynthesis. Expression of antibiotic biosynthesis may 
occur only under stringent environmental conditions.
2.4 SUMMARY
This chapter outlines some of the regulatory controls 
that may be relevant to antibiotic production in S. cattleya. 
The experiments included batch fermentation studies with 
S. cattleya, expression of antibiotic production was obtained 
in complex and in a chemically defined medium. Due to a 
significant degree of variability in the production of 
antibiotics by S. cattleya some possible causes of this 
observation are included here.
(64)
CHAPTER THREE
IDENTIFICATION OF g-LACTAM ANTIBIOTICS IN S. CATTLEYA
FERMENTATION BROTH
(65)
3. 1 INTRODUCTION
The carbapenem Thienamycin is produced by S t reptomyces 
cattleya, N-Acetylthienamycin, N-Acetyl-dehydro-
thienamycin, (160,161)^ N0rthienamycin, 8-Epithienamycin ^
Penicillin N, Cephamycin C , and a cyclopentenedione
antibiotic are co-produced in fermentation see Figure (3.1). 
Kahan et al , reported peak Thienamycin levels of
1.4 yg/ml. Thienamycin was purified usincj mild conditions, 
at or below 5°C and near neutral pH throughout, with an 
overall recovery of 1.64%, .
Isolation and purification of Thienamycin from S. cattieya 
fermentation broth, was not attempted here, due to its 
chemical instability and low fermentation productivity 
instead use of highly specific and sensitive assays permitted 
the detection and eventual identification of Thienamycin.
3.2 STRUCTURE—ACTIVITY RELATIONSHIP IN THE CARBAPENEM SERIES
Thienamycin possesses several novel structural features
when compared with the classical 8-lactams. The five merabered
ring contains a carbon in place of the more usual sulphur,
relative stereochemistry of the 5,6 8-lactam protons involves
a trans rather than cis relationship, and Thienamycin
incorporates an hydroxyethyl group in place of the customary
amide side chain of classical 8-lactams. Structural novelty
is paralleled by exceptional biological properties. Thienamycin
demonstrates very potent and broad spectrum antibacterial
activity, is resistant to attack by most bacterial
8-lactaraases, and is highly active against Pseudomonas sp., 
(.10,163,164,165)
(66)
FIGURE (3.1) ANTIBIOTICS CO-PRODUCED IN S. CATTLEYA 
FERMENTATION
Thienamycin (10)
R
OH
h7L
HoC
R1
'NH.
(10)
OH
N-Acetylthienamycin H ~~a
H,C
'NHAc
N-Acetyldehydro -
4.u- • (162)thienamycin
OH
HoC
8-Epithienamycin (162)
OH
H3C ^ L
H
'NH-
Northienamycin (162)
-NH-
NB: Penicillin N, Cephamycin C, Fig. (1.2)
and cyclopentenedione, Fig. (2.1) also produced.
(67)
Carbapen-3-em-2-carboxylic acid , Figure (3.2), the 
parent nucleus of Thienamycin and related carbapenems, 
demonstrates antibacterial activity of the same order of 
magnitude as the clinically used penicillins and cephalosporins, 
(166)^  Addition of the hydroxyethyl side chain at the 6
(16 7position further enhances potency of the carbapenem nucleus,
The C-6 side chain is also responsible for incorporation of
3-lactamase stability and properties of 3-lactamase inhibition
into the molecule. For maximal antipseudomonal activity
substitution of a basic function at the C-3 position is
required. The greater effectiveness of Thienamycin ( and
some analogues ) against Ps. aeruginosa has been attributed
to the Zwitterionic nature of the C-3 cysteaminyl side 
(21 162)chain, ' , N-acetylated products demonstrating reduced
4.- -4- (52>activity,
Antibacterial potency, 3-lactamase stability, and
3-lactamase inhibitory properties of carbapenems are dependent
on the stereochemistry of the 5,6 3-lactam protons, and the
C-6 hydroxyethyl side chain. The trans R configuration
found in Thienamycin appears to be optimal for both potency
(52)
and 3-lactamase stability, . For carbapenems with non
sulphated hydroxyethyl side chain, the antibacterial potency
(13 52 162)conferred by trans R configuration > cis S > trans S, ' 7
Trans R configuration gives the highest degree of 3-lactamase 
stability, trans S gives only moderate stability, and cis S 
low 3-lactamase stability. Sulphated derivatives ( with a 
sulphate group esterified onto the C- 8 hydroxyl ) with 8-S 
configuration demonstrate the highest degree of 3-lactamase 
inhibition, 8-S non sulphated carbapenems have a similar
FIGURE (3.2) THE STRUCTURES OF SQ 27860, N-FORMIMIDOYL 
THIENAMYCIN AND CILASTATIN
i) SQ 27,860 (58)
( Carbapen-3-em
-2-carboxylie acid )
co2h
ii) N-Formimidoy1
. (163)thienamycin
. . .. , . . . (1 1) in) Cilastatm
/ N H 2
' C ^ H
(69)
(169)
/
Spectrum of 3-lactamase inhibition but are less potent,
carbapenems with 8-R configuration are poor 3-lactamase
. . .... (20,168) inhibitors, .
The highly strained nature of the carbapenem nucleus, 
together with novel structural properties responsible for 
the exceptional activity of Thienamycin, also contrbute 
to its chemical instability. At high concentration an 
intermolecular reaction may occur, between the cysteamine 
residue of one molecule with the azetidinone of a second 
molecule, thereby inactivating Thienamycin. The problem 
is circumvented by use of the N-formimidoyl derivative, (H/1^3) 
a discovery a great significance in the clinical development 
of Thienamycin.
Subsequent sections deal with the development of assay 
techniques, to allow detection of the 3-lactams co-produced 
in S. cattleya fermentation broth, and to permit their 
differentiation on the basis of the structure-activity 
relationship here outlined, see Table (3.1).
(70)
TABLE 3.1
ANALYTICAL TECHNIQUES USED IN THE DETECTION AND IDENTIFICATION 
OF CARBAPENEMS PRODUCED IN S. CATTLEYA FERMENTATION
1) 6-lactamase INDUCTION
2) 6-LACTAMASE INHIBITION
3) ANTIBACTERIAL ASSAYS
4) HYDROXYLAMINE EXTINGUISHABLE ABSORBANCE
( X 299 nm ), AND DIFFERENTIAL SPECTROPHOTOMETRY
5) DEACYLATION OF N-ACETYLATED CARBAPENEMS USING 
ACYLASE 1
6 ) SUSCEPTIBILITY OF CARBAPENEMS TO RENAL 
DIPEPTIDASE
7) CHROMATOGRAPHY, TLC, H.P.L.C.
(71)
3.3 ANALYTICAL TECHNIQUES
3.3.1 g-Lactamase Induction
g-lactam antibiotics are capable of inducing the synthesis 
of g-lactamase in both Gram positive and Gram negative 
organisms, f Figure (3.3) illustrates a possible model
for the regulation of g-lactamase production. Recently 
workers at Squibb have published details of a g-lactamase 
induction assay, used to screen for g-lactams in fermentation 
broth, . A strain of Bacillus lichen if ormis was employed,
which in the absence of an inducer, i.e. g-lactam, produced 
minimal amounts of g-lactamase. However, in the presence of 
a g-lactam a large amount of the enzyme was produced and 
could be detected by the use of a chromogenic cephalosporin 
substrate,
A g-lactamase induction assay ( property of ICI 
Pharmaceutical PLC ) was used for the detection of g-lactam 
antibiotics in S. cattleya fermentation broth. The assay 
proved highly specific for g-lactams, and enabled detection 
down to nanogram levels. Interestingly a false positive was 
obtained with the dipeptidase inhibitor, Cilastatin, ,
whose structure is shown in Figure (3.2 iii). The induction 
assay permitted detection of g-lactams, in liquid media 
( whole fermentation broth, H.P.L.C. fractions ) see 
Figures (3.10), (3.17 - 3.19), and by the use of a TLC-
bioautographic approach, see Figures, (3.12), (3.13a).
3.3.2 3-Lactamase Inhibition
Screening of microorganisms for naturally occurring 
g-lactamase inhibitors lead to the discovery of, Clavulanic
(72)
FIGURE (3.3)
MODEL PROPOSED FOR THE REGULATION OF 8-LACTAMASE PRODUCTION,^64)
Pen A
DNA DNA
P O Pen P Pen I
/
6-lactam 
^  (inducer)
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/
Antirepress or Repressor
*
Repressor/Antirepressor complex
P and O are the proraotor and operator sequences for the 
penicillinase structural gene (Pen P). Pen I is a regulatory 
gene specifying the penicillinase repressor, Pen A is a 
regulatory region specifying a penicillinase antirepressor 
protein. Formation of the repressor/antirepressor complex 
takes place in the presence of an inducer, thereby inactivating 
the penicillinase repressor. Subsequently transcription 
occurs and penicillinase synthesis begins.
(73)
acid, , and the Olivanic acids, . Subsequently
other 3-lactam antibiotics were shown to act as 3-lactamase 
inhibitors, .
3-Lactam antibiotics in the carbapenem series differ 
in their 3-lactamase inhibitory properties, dependant on 
their stereochemistry. Compounds with 8R configuration, 
such as Thienamycin and N-Acetylthienamycin, are reportedly 
only poor 3-lactamase inhibitors, ^20  ^. However Thienamycin 
has been shown to be a relatively potent 1 suicide ' 
inhibitor of the Enterobacter cloacae P99 3-lactamase , ^ .
The E. cloacae P99 3-lactamase was prepared, and used 
in an inhibition assay to detect carbapenems in S. cattleya 
fermentation broth. Inhibition of the enzyme could be 
detected in liquid or solid media using the chromogenic 
substrate Nitrocefin,(171). when hydrolysed by 3“lactamase 
Nitrocefin undergoes a distinct colour change from yellow 
to red, see Figure (3.4a). Antibiotic standards 
Cephalosporin C, Cephamycin C, Deacetoxycephalosporin C 
failed to inhibit P99 at concentration < 100 yg/ml,
Penicillin N demonstrated one well of enzyme inhibition at
100 jjg/ml but did not inhibit the enzyme at lower concentrations.
A comparison of the P99 inhibitory properties of, N- 
Forraimidoyl thienamycin, MM13902, MM 22383, MM 22382, was 
made, Figure (3.4b). Structures of the carbapenem standards 
are given in Figure (3.5 ). MM 13902 and MM 22382 appear to 
be more potent inhibitors ( approx. 100 fold ) of the P99 
3-lactamase, than N-Formimidoyl thienamycin or MM 22383.
This observation is in agreement with predicted properties 
on the basis of their stereochemistry.
(74)
FIGURE (3.4)
SHOWING THE E. CLOACAE P99 g-LACTAMASE INHIBITION ASSAY
a) Inhibition of P99 g-lactamase by N-Formimidoyl thienamycin
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C- row 12Nitrocefin control ( enzyme blank )
(+) - Nitrocefin hydrolysed by g-lactamase, colour change 
yellow to red.
(-) - Nitrocefin not hydrolysed, no colour change.
FIGURE (3.4)
b) Comparative Inhibitory Properties of Carbapenem Standards
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FIGURE (3.5)
STRUCTURAL CONFIGURATION OF CARBAPENEM STANDARDS
R
MM13902: sulphated O S O 3 H
Olivanic acid, cis 8S '
HjC-yL
H
O HMM22 382: hydroxy 
Olivanic acid, cis 8S u n -
H
C 0 2H
MM22 383: hydroxy
_R  _____
O H
trans 8S ^ 7
H
O H
N-Formimi doy1 
-thienamycin H " a
trans 8R
Structure references as given in Figure (1.3)
3.3.3 Assays based on Antibacterial Activity
Antibacterial assays were used to monitor antibiotic 
production during S. cattleya fermentation. Activity was 
detected using TLC-bioautography, and broth dilution assays 
( see Experimental ). The test organisms used were 
Staphylococcus aureus Oxford H, strain VI, Comamonas terigena 
ATCC 8461, (1^ 3) ^ a strain of Escherichia coli super­
sensitive to 3“lactam antibiotics ( obtained from ICI 
Pharmaceuticals PLC ). Differential susceptibilities of the 
test organisms to 8 “lactam standards are shown in Table (3.2).
Figures (3.13c), (3.13d) show TLC-bioautographic 
analysis of the antibiotics in S. cattleya fermentation broth, 
and their relative activities vs the test organisms.
Subsequent Figures (3.14a-c) demonstrate the susceptibility 
of these broth components to hydroxylamine and Dipeptidase 1 
( see later sections ). A component (I), Figure (3.13c), 
with 0.87, demonstrated antibacterial activity against 
E. coliss, but not C. terigena or S. aureus, failed to 
induce g-lactamase, and was not susceptible to hydroxylamine 
or Dipeptidase 1. It is suggested that this component may 
have been the cyclopentenedione antibiotic produced by 
S. cattleya, d41) .
Figures (3.17 - 3.19) show H.P.L.C. analysis of 
S. cattleya fermentation broth, and the detection of 
antibacterial activity in fractions using the M.I.C. 
colorimetric assay ( broth dilution assay ). Attempts were 
made to assign the antibacterial activity observed in 
fermentation broth to the presence of a particular 8-lactam, 
on the basis of different intrinsic susceptibility of the 
test organisms, and the known fermentation products of
(78)
TABLE (3.2)
DIFFERENTIAL SUSCEPTIBILITIES OF TEST ORGANISMS TO fi-LACTAM 
ANTIBIOTICS AS DETERMINED USING THE MIC COLORIMETRIC ASSAY
M.I.C. (yg/yl) 
(approx. 1 0  ^
CFU/WELL)
E. COLISS S. AUREUS C. TERIGENA
PENICILLIN N 0. 31 - 1.25-2.50 8 0 . 0
CEPKAMYCIN C 0.31-0.62 8 0 . 0 1 0 . 0
cephalosporin c O. 15 40.0 40.0
DE ACETOXY- 
CEPHALOSPORIN € 0.62 >8 0 . 0 >80.0
PS-5 0.62 O.31-0.62 2 0 . 0
N-FORMIMIDOYL
THIENAMYCIN 0.078 0.0045 0. 15
MIC COLORIMETRIC ASSAY : TEST ORGANISMS E. COLISS,
S. AUREUS and C. TERIGENA
(79)
(126)
S. cattleya, . This strategy appears to have been 
successful in the case of the major 3-lactam product,
Thienamycin, good correlation was observed between estimates 
of antibiotic concentration using the different assays. For 
the minor fermentation products the results were somewhat 
inconclusive, due to a lack of appropriate 3-lactam standards 
and the very low fermentation yield of these components.
3.3.4 Hydroxylamine Extinguishable Absorbance 299 nm
The highly strained carbapenem nucleus thought to confer 
exceptional biological activity, may also be responsible for 
chemical instability of the molecule, rendering it highly 
susceptible to nucleophilic attack, . Kahan et al
observed that a coordinate loss of bioactivity, and 
absorbance in the 300 nm region of the UV spectrum, occurred 
when Thienamycin was exposed to unusually low concentrations 
of hydroxylamine or cysteine,  ^  ^. Carbapenems other than
Thienamycin have also been shown to possess a hydroxylamine 
extinguishable UV chromophore, m^ax 297 ^ 300 nm, 0-4,162)^
During the course of the work, this property of 
carbapenems has proved particularly useful. At low concentration 
( 8 yM/ml ) hydroxylamine could extinguish the UV chromophore 
of N-Formimidoyl thienamycin, see Figure (3.6). Concommitant 
loss of antibacterial activity, 3-lactamase inhibitory 
properties, and the ability to induce 3-lactamase formation 
was observed, Figures (,3.14a-c), presumably these activities 
are dependent on the presence of an intact 3-lactam ring.
At the concentration used hydroxylamine had no apparent 
effect on Cephamycin C and the other 3-lactam standards,
(80)
FIGURE (3.6)
SHOWING THE N-FORMIMIDOYL THIENAMYCIN, HYDROXYLAMINE 
EXTINGUISHABLE ABSORBANCE , X 299 nm
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0N-Formimidoyl thienamycin ( 10 yg/ml ) incubated at room 
temperature, with hydroxylamine, final concentration
8 yM/ml, loss of absorbance 299 nm recorded.']
(81)
TABLE (3.3)
EFFECT OF HYDROXYLAMINE ON g-LACTAM STANDARDS
FINAL
CONCENTRATION 
OF NH2OH (pM. ml 4.0 8.0 16.0 32.0 Control
N-FORMIMIDOYL
THIENAMYCIN
16.0 0 O 0 49.0
CEPHAMYCIN C 30.0 30.0 30.0 30.0 30.0
CEPHALOSPORIN C 27.0 2 7.0 27.0 27.0 27.0
DEACETOXY
CEPHALOSPORIN C 17.0 17.0 17.0 17.0 17.0
PENICILLIN N 6 .0 0 0 0 28.0
DIAMETER OF INHIBITION ZONE / (mm) : E. Coliss TEST
ORGANISM, 1 pg STANDARD USED TO PRODUCE THE INHIBITION 
ZONE, LOADED AS A SINGLE SPOT ON WHATMAN No. 1 PAPER AND 
OVERLAYED ON E. coliss SEEDED AGAR
FIGURE (3.7)
UV DIFFERENCE SPECTRA
SAMPLE FOLLOWING INCUBATION WITH NH2OH 
SAMPLE PRIOR TO INCUBATION WITH
n h2oh
(A) N-Formimidoyl 
thienamycin 
(2o yg/ml)
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fraction (II)
See Figure (3.18)
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TO OBTAIN DIFFERENCE SPECTRA:
Samples scanned in the region 401.5-187 nm, incubated with 
hydroxylamine (8ym/ml) at room temp for 25 min. and then 
rescanned.
ABSORBANCE/ARBITRARY 
UNITS 
ABSORBANCE/ARBITRARY 
UNITS
although Penicillin N was susceptible, Table <3.3).
Hydroxylamine extinguishable absorbance was used to detect 
carbapenems in S. cattleya fermentation broth, Figures 
(3.14a-c).
Differential spectrophotometry was used in conjunction 
with H.P.L.C. to detect carbapenems in fermentation broth, 
the UV chromophore was of value when chemically defined 
growth medium was used. Where complex medium was used the 
presence of intact 3-lactam was demonstrated by 3-lactamase 
induction, 3-lactamase inhibition or antibacterial assay.
The difference spectrum for the H.P.L.C. fraction thought to 
contain the Thienamycin component ( fraction No. (11),
Figure (3.18)), resembled that of the N-Formimidoyl thienamycin 
standard, Figures (3.7a),(3.7b). When fraction (11) was 
allowed to react with hydroxylamine, a loss of absorbance in 
the 300 nm region was observed, with simultaneous increase in 
the 2 0 0 nm region, indicating that this component may 
indeed be Thienamycin.
3.3.5 Deacylation of N-acetylated Carbapenems
N-acetylated carbapenems are less active antimicrobially,
than their counterparts possessing a free C-3 cysteaminyl
side chain. Reduction in activity is markedly apparent for
(52)Pseudomonas sp., . The deacetylation of PS-5 to NS-5
(15)by L and D amino acid acylases has been reported, ,
see Figure (3. 8) .
An attempt was made to design an assay which would allow 
the deacetylation of N-acetylcarbapenems produced in S . cattleya 
fermentation, and thereby permit their identification. PS-5
(84)
was used as a standard to determine the incubation conditions. 
Carbapenem standard was incubated with Acylase 1 ( Sigma ), 
the mixture was separated by T.L.C. and 3-lactams detected 
bioautographically using the 6-lactamase induction assay,
Figure (3.8) t under the conditions used PS-5 has an
value of 0.73, and N-Formimidoyl thienamycin an R^ of 0.39.
In the reaction mixture a new 3“lactam product in addition 
to unchanged PS-5, was detected with R^ 0.49, presumably the 
deacetylated analogue NS-5.
A long incubation period was required to ensure detection
of product formation. Incubation could not be prolonged
indefinitely as the product itself appeared to be unstable,
possibly due to the presence of a free amino group on the C-3 
(15)side chain, . The activity of the acylase was marginally
2 +  (172)increased by Co enzyme ' activation 1, . To enable
detection of the deacetylated product a high concentration of
PS-5 ( 20 yg/ml ) was necessary in the incubation mixture.
However it was not possible to achieve concentrations, of
minor broth components, of this order in fermentation.
Following unsuccessful attempts to concentrate the individual
minor broth components in H.P.L.C. fractions by freeze-drying
this approach to the identification of N-acetylated carbapenems
was abandoned.
3.3.6 Susceptibility of Carbapenems to Renal Dipeptidase
Investigators at Merck discovered that Thienamycin and
related carbapenems were extensively metabolised in vivo,
(12 1 73 )predominantly in the kidney, ' . The renal enzyme,
Dipeptidase 1 ( Dehydropeptidase ) E.C. 3.4.13.11., was
(85)
FIGURE (3.-8) 
DEACETYLATION OF PS-5 BY ACYLASE 1
--------------------------   SF
ooooooo
 --- 1--- 1----1--- 1--- 1--- 1---1----1----- OR
PS-5 .1 2 3 4 5 6 NFT
20 yl loaded/track
fPS-5 ( 20 yg/ml ) incubated with Acylase 1, at 37°C,
2+ -4Co 10 M. T.L.C. performed on Whatman LK 6DF plates 
with solvent system, ethanol:phosphate buffer ( lO mM, 
pH 7.0 ) , 7:3. 3-Lactam zones detected bioautographi-cally 
using 3-lactamase induction assay]
PS-5, PS-5 control ( 20 yg/ml )
NFT, N-Formimidoyl thienamycin control(10 yg/ml)
1,2 ,3 ,4 ,5,6 ,PS-5 incubated with Acylase 1, respective 
incubation period 0, 0.5, 1.0, 1.5, 2.0 and 2.5 Hours.
SF - Solvent front 
OR - Origin
found to be responsible for the metabolism of carbapenem 
antibiotics, which exhibit a structural homology to dehydro­
peptides, Figure (3. 9 ). Carbapenems and penems were found 
to be susceptible to hydrolysis by the Dipeptidase, whereas 
cephalosporins appeared to be insensitive to attack by the 
enzyme.
Carbapenem 3-lactams vary in their susceptibility to
hydrolysis by renal Dipeptidase, compounds with free C-3
cysteaminyl side chain being more stable than their N-acyl 
( 12 )analogues, . Non basic N-acylated Thienamycin and
naturally occurring N-acylated carbapenems were found to
degrade 4 to 50 fold faster than Thienamycin when exposed to
(12)enzymatic hydrolysis by the Dipeptidase, .
Renal Dipeptidase was prepared ( see Experimental ), and 
used to detect carbapenems ( and penems ) in S. cattleya 
fermentation broth. Action of the enzyme on carbapenems was 
visualised as loss of, antibacterial activity, 3-lactamase 
inhibitory properties, and ability to induce 3-lactamase 
formation, Figure (3.l4a-c). A comparison of the susceptibility 
of 3-lactam standards to Dipeptidase 1 is available in 
Table (3.4) .
S. cattleya co-produces both unacetylated, and N-acetylated
(160,161,162) , . 
carbapenems, , known to vary m  their susceptibility
to Dipeptidase 1. The 3”lactam components in S. cattleya
fermentation broth were separated by H.P.L.C., Figure (3.10).
Relative susceptibility of the 3“lactam fractions to Dipepidase
1 was determined, N-Formimidoyl thienamycin and PS-5 were
used as standards, Figure (3.11). 3-lactam components in
fractions III, IV and V ( i.e. 'late off ' fractions ) and
(87)
FIGURE (3.9)
POSTULATED STRUCTURAL HOMOLOGY BETWEEN THIENAMYCIN AND 
DEH YDROPEPTIDE S (12)
nh2
Lehyropeptide
C for example 
Glycyldehydro 
phenylalanine 
R ■= NH2
RV = Phenyl )
Arrows indicate site of hydrolysis by Dipeptidase
R-
N-
° "I
Thienamycin r ~
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TABLE (3.4)
SUSCEPTIBILITY OF $-LACTAM STANDARDS TO DIPEPTIDASE 1
ANTIBIOTIC
CONCENTRATION 50 25 10
(yg/ml) DHP CONTROL DHP CONTROL DHP CONTROL
PENICILLIN N 24 25 18 19 12 12
CEPHAMYCIN C 28 28 23 23.5 17 16.5
N-FORMIMIDOYL
THIENAMYCIN
33.5 46 29 38 17.5 26
CEPHALOSPORIN C 27 27 24 24 19.5 19.5
DEACETOXY
CEPHALOSPORIN C 20.5 2 1 17.5 17.5 13.5 13.5
DIAMETER INHIBITION ZONE / (mm), 20 yl LOADED ONTO 
WHATMAN ANTIBIOTIC ASSAY DISCS ( 6.35 mm ) AND PLACED 
ON E. COLISS SEEDED AGAR
FIGURE (3.10)
H.P.L.C. SEPARATION OF COMPONENTS IN S. CATTLEYA
FERMENTAION BROTH / PRIOR TO DE T E RMI NAT I ON OF THEIR 
SUSCEPTIBILITY TO DIPEPTIDASE 1/ FIGURE (3.11)
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8-Lactamase induction assay 
M.I.C. assay vs. S. aureus
H.P.L.C. conditions : column 4 mm ID x 250 mm (Technicol 
LiChrosorb), 500 yl injection loop, eluant 10 mM
phosphate buffer pH 7.0, t to t2Q minutes, t20 to t30
15% methanol gradient added, elution up to t^Q at 15%
MeOH, flow rate 1.2 ml/min., fractions collected 1 minute 
intervals
Sample : S. cattleya fermentation broth, Kahan medium (E)
9 4 hours ( 2^ '^ growth curve given Figure (2.3).
8-Lactams located in fractions using 8-lactamase induction 
and MIC broth dilution assays, ( ) on Y axis indicate
corresponding well on dilution plate
N.B. : incubation of broth with NH2OH ( conditions as
given Figure (3.7) prior to H.P.L.C., reduced 
all values to zero.
FIGURE (3.11)
RELATIVE SUSCEPTIBILITY OF g-LACTAM COMPONENTS IN S. CATTLEYA
FERMENTATION BROTH, TO DIPEPTIDASE 1
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I,II,III,IV,V, H.P.L.C. fractions, with respective retention
times, 7, 13, 3 3, 36 and 41 minutes, see Figure (3.10)
(i) N-Formimidoyl thienamycin (ii) PS-5
S. cattleya fermentation broth subjected to H.P.L.C. analysis, 
Figure (3.10), fractions I-V incubated with Dipeptidase (DHP) 
at 37°C, 0-30 minutes, remaining activity determined using 
8-lactamase induction assay ( section 4.3.7.3 )
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FIGURE (3.12)
THIN LAYER CHROMATOGRAPHY OF 3-LACTAM COMPONENTS IN S. CATTLEYA 
FERMENTATION BROTH/ PREVIOUSLY SEPARATED BY H.P.L.C.,
FIGURE (3.10)
£t.L.C. performed on Whatman LK 6DF plates, solvent system, 
ethanol:phosphate buffer ( 10 mM, pH 7.0 ) 7:3.
Carbapenem controls, PS-5, N-Formimidoyl thienamycin,
(15 yg/ml), 20 yl loaded/track 3-Lactam zones detected bio- 
autographically using 6-lactamase induction assayJ 
SF - Solvent front, OR - Origin
Zones indicate regions of 6-lactamase induction and therefore 
presence of 6-lactam, where 2nd zone observed within induction 
zone this was due to antibacterial activity of inducing 
6-lactam vs. B. licheniformis
Relative susceptibility of I, II, III, IV and V, to 
Dipeptidase 1 determined, Fig. (3.11).
SF
o
' I I--------I---------- 1----- 1-------- 1--------1---------r----1— OR
NFT PS- 5 7 12 13 33 36 41 48
I II III IV V
H.P.L.C. Fraction No (Fig. 3.10) 
250 yl loaded/track
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PS-5 standard appear to be significantly more readily 
hydrolysed by the Dipeptidase than Thienamycin or the ' early 
off * fractions, I and II. This observation may indicate 
that the 1 late off 1 fractions contain N-acetylated or 
N-acylated carbapenems.
3.3.7 Chromatographic Systerns 
3.3. 7.1 Thin Layer Chromatography ( T.L.C. )
Thin layer chromatography was used to separate the 
3-lactams co-produced in S. cattleya fermentation broth.
values for the 3-lactam standards are given in Table (3.5).
3-Lactams were located on the T.L.C. plate using a bioauto­
graphic technique with 3-lactamase induction, 3-lactamase 
inhibition, or antibacterial assays.
Figures (3.13a-d) show T.L.C. separation and detection 
of 3-lactam components in S. cattleya broth, Kahan medium (E) 
and defined medium (C) ( see later H.P.L.C. analysis of
identical fermentation broth ). Susceptibility of the 
different components in S', cattleya broth ( Kahan medium (E) ,
9 4 hours (f2 ))# to hydrolysis by hydroxylamine and Dipeptidase 1 
are shown in Figures (3.14a-c).
Dilution of fermentation broth allowed resolution of 
possibly three 3”lactam components in the 0.36 - 0.56 
region, and possibly three more 3-lactams in the 0.65 - 0.81 
R^ region, detected by 3-lactamase induction. H.P.L.C. 
analysis was therefore carried out to obtain better resolution 
of these components.
An attempt was made to relate the H.P.L.C. separation of 
B-lactam components. Figure (3.10), to the situation observed
(93)
TABLE (3.5)
THIN LAYER CHROMATOGRAPHY: Rf VALUES FOR 3-LACTAM STANDARDS
SOLVENT SYSTEM
R. VALUES r ETHANOL: lOmM P04 7:3
ACETONITRILE: 
WATER 7:3
BUTANOL:
ACETIC
ACID:
WATER
4:1:1
PENICILLIN N 0.72 0.36 0 . 12
CEPHAMYCIN C 0 . 6 8 0.33 0.08
CEPHALOSPORIN C 0 . 71 0.34 0.05
DEACETOXY 
CEPHALOSPORIN C
0.65 0.32 0.07
N-FORMIMIDOYL
THIENAMYCIN
0.39- 
0. 44
0 . 2 1 1.1. 
T.S.
THIENAMYCIN 0.39 NT NT
PS-5 0.75 NT NT
N.T.: NOT TESTED
I.I.T.S.: INACTIVATED IN THIS SYSTEM
(94)
FIGURE (3.13)
T.L.C. SEPARATION OF COMPONENTS IN S. CATTLEYA FERMENTATION
BROTH
(A) 3”Lactamase Induction Assay
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(B) P99 8-Lactamase Inhibition Assay
NFT
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(f2) (f3)
£ T.L.C. performed, Whatman LK 6DF plates, solvent system, 
ethanol:phosphate buffer ( 10 mM, pH 7.0 ) , 7:3. Broth 
components detected bioautograghically, control NFT 
2 0 yg/ml, 2 0 yl standard or broth loaded/track]
S. cattleya fermentation broth ( growth curve Figure ( 2 . 3 ) )  , 
(f2) indicates Kahan Medium (E), fermentation time given 
in hours, (f3) indicates mycelium resuspended in defined 
medium / samples labelled as corresponding time in
parent fermentation, (f3)*
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FIGURE (3.13)Continued.
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FIGURE (3.14) SHOWING THE EFFECT OF HYDROXYLAMINE AND 
DIPEPTIDASE 1 ON COMPONENTS IN S. CATTLEYA FERMENTATION BROTH
(A) B-lactamase Induction Assay
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O ©
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NFT NFT 9 4 9 4 NFT NFT 94 9 4
+ + + +
DHP DHP
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(B) P99 B-lactamase Inhibition Assay
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T.L.C. performed as Figure (3.13)
S', cattleya fermentation broth, (f2) 94 hours Kahan medium (E) , 
used throughout, control, NFT 20 yg/ml
Susceptibility to Dipeptidase 1 : Sample and control 
incubated with DHP at 37°C for 30 min.
Susceptibility to hydroxylamine: Sample and control incubated
with NH20H (8ym/ml) at room temp, for 2 5 min.
FIGURE (3.14) continued.
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with T.L.C., Figure (3.12). The H.P.L.C. fraction with 
retention time (Rt) 36 minutes revealed three g-lactam 
components on further T.L.C., with R^ values 0.47, 0.70, 
0.77. This may indicate that one of the components with 
higher R^ was being converted to its deacylated analogue 
( see section 3.3.5 ).
Thin layer chromatography permitted separation, and 
detection, using 8-lactamase induction and 8“lactamase 
inhibition assays, of minor components in the N-Formimidoyl 
thienamycin standard. These minor components appeared to 
be carbapenems as they were susceptible to hydrolysis by 
hydroxy lamine and Dipeptidase 1. At very high concentrations 
of the NFT standard, > lOOjjg/ml, antibacterial activity 
( vs S. aureus ) was detected for these components. Edward 
0. Stapley ( personal communication ) suggested that these 
minor impurities could be minor broth components ( or their 
N-formimidoyl derivatives ) produced by S. cattleya, as our 
NFT standard had been prepared from a fermentation batch 
of Thienamycin. Later H.P.L.C. analysis of the NFT standard 
revealed that it also contained some unchanged Thienamycin.
3.3.7.2 High Performance Liquid Chromatography H.P.L.C.
High performance liquid chromatography was used to 
separate the 8-lactams in S. cattleya fermentation as this 
gave better resolution of components than that obtained with 
T.L.C. Retention times (Rt)for the 8-lactam standards are 
given in Table (3.6). Different retention times were 
observed for the NFT standard, depending on the column 
packing material, Figure (3.15) shows retention of NFT with
TABLE (3.6)
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY: RETENTION TIME (Rt) 
FOR B-LACTAM STANDARDS
SPHERISORB5 ODS 1 
RETENTION TIME(Rfc) 
(A) (B)
TECHNICOL
RETENTION
(A)
^18
TIME(Rt)
(B)
PENICILLIN N 14.0 - NT NT
CEPHAMYCIN C 9.0 8.4 NT NT
CEPHALOSPORIN C 35.0 34.5 NT NT
DEACETOXY 
CEPHALOSPORIN C
13.0 12.3 NT NT
N-FORMIMIDOYL
THIENAMYCIN
38.0 37.5 19.0 19.0
THIENAMYCIN 27.0 26.4 NT NT
PS-5 44.0 43.6 38.0 37.7
(A): Rt AS DETERMINED BY M.I.C. COLORIMETRIC ASSAY : E.COLISS
(B): R y  A S  DETERMINED BY U.V. SPECTROPHOTOMETRY A 260 nm,
(A 299 nm FOR CARBAPENEMS)
N.T. : NOT TESTED
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FIGURE (3.15)
H.P.L.C. RETENTION TIME FOR N-FORMIMIDOYL THIENAMYCIN WITH 
TECHNTCOL LiCHROSORB COLUMN PACKING
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H.P.L.C. conditions: Column 4 mm I.D. x 250 mm (Technicol
LiChrosorb), 500 yl injection loop, eluant 10 mM phosphate 
buffer pH 7.0, tQ to t2Q minutes, t2Q to t3Q 15% methanol 
gradient added, elution up to t6Q at 15% MeOH. Flow rate
I.2 ml/minute, fractions collected 1 minute intervals.
N-Formimidoyl thienamycin : 0.15 yg/ml in 10 mM phosphate 
buffer pH 7.0 . Retention time (Rfc) for NFT determined 
using 6-lactamase induction and M.I.C. broth dilution assays
FIGURE (3.16)
H.P.L.C. RETENTION TIME FOR THIENAMYCIN AND N-FORMIMIDOYL
THIENAMYCIN, WITH SPHERISORB 5 OPS 1 COLUMN PACKING
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H.P.L.C. conditions, as Fig. (3.15), Spherisorb 5 0DS1, standard used 
at 25 yg/ml, R determined using M.I.C. broth dilution assay, and UV 
absorbance 299 nm.
H.P.L.C. SEPARATION OF OOMPOSIENTS IN S. CATTLEYA IERMENTATICN BROTH,
( KAHAN MEDIUM (E) )
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H.P.L.C. Conditions: as Fig. (3.15), Technicol LiChrosorb 
Sample: S. cattleya broth, Kahan medium (E) 94 hours (£2 ) , 
growth curve Fig. (2.3)
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H.P.L.C. SEPARATION OF COMPONENTS IN S. CATTLEYA FERMENTATION
BROTH/ ( DEFINED MEDIUM)
256
128(A) 8-Lactamase 
Induction and 
MIC Broth 
Dilution Assays
— Ind.
— S.aureus
C.terigena
64
32
50 604020
(B) P99 Inhibition 
Assay
3
2
1
50 6040
100
(C) UV
Absorbance w 80
2 9 9 nm h
6 70
w 60ch <C
(n m
r< 50
H voU H 40
m i w 30 So j 
o <  
w w u 20
 ^o 10 > 0) oU) " i—I
50 60405 10 20 30
FRACTION n o . /RETENTION TIME (R. ) (MINUTES)
H.P.L.C. Conditions: as Fig. (3.15)., Technicol LiChrosorb 
Sample: S. cattleya broth, defined medium, 118 hours (f3) , 
growth curve Fig. T2.3)
Technicol LiChrosorb packing. Figure (3.16) shows the 
retention of NFT and of authentic Thienamycin standard with 
Spherisorb 5 ODS 1 packing, ( NB. NFT standard appears to 
contain some unchanged Thienamycin ). The different retention 
times observed for the NFT standard, probably reflect a 
difference in carbon loading of the column packing material.
The H.P.L.C. system used here was a modification of that 
of Wilson et a l , , who indicated that Thienamycin was 
less well retained than NFT. An observation that can be 
explained by the more polar nature of Thienamycin, when 
compared with its N-formimidoyl derivative. Thus prior to 
obtaining the Thienamycin standard from Merck, the Thienamycin 
component in S', cattleya broth was tentatively assigned as a 
g-lactam with retention time less than that of the NFT standard.
Separation by H.P.L.C., of the g-lactam components in 
S. cattleya fermentation broth ( Kahan medium (E) ) is shown 
in Figure (3.17). Figure (3.18) shows the separation of 
8-lactam components when the defined medium was used, and 
illustrates the value of the UV chromophore of Thienamycin,
( X 299 nm ). This UV absorption of carbapenems could not 
be applied to complex fermentation broth, for example 
medium (E), due to the high UV background.
The major 8-lactam component in S. cattleya broth had 
a retention time (Rt) of 11/12 minutes, notably less than 
that of the NFT standard ( R^ 19 minutes ), with Technicol 
LiChrosorb packing. In addition several other 8”lactam 
components were detected, a number having considerably longer
retention time than NFT, suggesting they were of a less polar 
nature, and supporting the view that these components could
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H.P.L.C. SEPARATION OF COMPONENTS IN S. CATTLEYA FERMENTATION
BROTH, ( KAHAN MEDIUM (E) ), WITH SPHERISORB 5 OPS 1
COLUMN PACKING
(A) M.I.C. Broth 
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H.P.L.C. Conditions: as Figure (3.15), Spherisorb 5 ODS 1
Sample: S. cattleya Fermentation broth Kahan medium (E),
9 4 hours (f2 ), growth curve Figure (2.3).
Broth used here identical to that in Figure (3.17)- note 
effect of column packing on (Rt) of major 6-lactam component
be N-acylated carbapenems. Figure (3.19) demonstrates the 
effect of hydroxylamine on the 3-lactam components in 
fermentation broth. Relative susceptiblity of the different 
3-lactams to hydrolysis by Dipeptidase 1 is discussed in 
section (3.3.6).
H.P.L.C. separation of 3-lactams in S. cattleya 
fermentation broth, was also performed using Spherisorb 5 
ODS 1 packing. Identical broth was used, so a direct 
comparison can be made between Figure (3.17) and (3.19).
With Spherisorb packing the retention time (Rt) of the major 
3-lactam component was 29 minutes, (Rt)for NFT was 38 minutes 
and 2 7 minutes for the authentic Thienamycin standard.
3.4 IDENTIFICATION OF 3-LACTAMS IN S. CATTLEYA FERMENTATION
BROTH
3.4.1 Thienamycin
On the following criteria Thienamycin was identified in
S. cattleya broth as a component that :-
i) Demonstrated the ability to induce 3-lactamase formation 
in B. 1 icheniformi s
ii) Demonstrated the ability to inhibit P99 3-lactamase.
iii) Demonstrated antibacterial activity vs S. aureus,
C. terigena, and E. coliss
iv) Demonstrated susceptibility to hydroxylaime at low
concentration, and gave the desired difference spectrum
v) Demonstrated susceptibility to renal Dipeptidase 1, of
the same order as the N-Formimidoyl thienamycin standard,
iv) Demonstrated a close correlation with expected R^ value
on T.L.C.
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vii) Demonstrated a close correlation with expected R^ on
H.P.L.C.
3.4.2 Minor Broth Components
In addition to the major fermentation product Thienamycin, 
several minor broth components were detected, Figures(3.17, 
3 .1 8 , 3.19), which acted as inducers for 8 -lactamse formation 
in B. licheniformis. These components were initially 
detected by their ability to inhibit the P99 8-lactamase, 
which appeared to be superior to that of the NFT standard. 
Susceptibility of these components to hydroxylamine and 
Dipeptidase 1 suggested they were carbapenems. In some cases 
they were hydrolysed more readily by the Dipeptidase, than 
the NFT standard.
The minor broth components may be carbapenems of the 
N-acetylated or N-acylated variety ( their mobilities on T.L.C. 
and H.P.L.C. suggest they are of a less polar nature than 
NFT ), with varying stereochemistry, which would account for 
their 8-lactamase inhibitory properties.
3.5 SUMMARY
This chapter covers a number of analytical techniques, 
used in the detection and identification of Thienamycin and 
co-produced 8-lactam antibiotics, in S. cattleya fermentation 
broth.
Assays were designed to discriminate between co-produced 
carbapenems and 8”lactams on the basis of their structure- 
activity relationships.
The major 8-lactam fermentation product was identified 
as Thienamycin.
(108)
CHAPTER FOUR
EXPERIMENTAL
(109)
4.1 CULTURE MAINTENANCE
Streptomyces cattleya NRRL 8057 was obtained, as freeze 
dried ampoules , from ICI Pharmaceuticals PLC. The organism 
was incubated on Malt-Yeast agar (g/L, malt extract, 10.0, 
yeast extract, 4.0, glucose, 4.0, bacteriological agar 
( Oxoid No. 1 ), 20.0 ) , at 25°C for a period of 14 days.
Spore suspensions were prepared by pipetting a solution of 
50% glycerol : 50% distilled water, onto the surface of the 
agar, spores were evenly dispersed by gentle pipetting.
Spore counts were carried out as follows; the suspension
-2
was serially diluted in 0.85% saline, over the range 10 -
10 °^, 0 . 1 ml of each dilution was spread on the surface of 
an agar plate, all operations being carried out in duplicate. 
Colony counts were performed after incubation of plates at 
25°C for 3 days. The spore suspension diluted to 1 x 10^ 
c.f.u/ml, was stored in aliquots at -20°C.
4.2 BATCH FERMENTATION OF S. CATTLEYA
4.2.1 Preparation of Seed Inoculum, (f^ )
The spore suspension was allowed to come to room 
temperature, 0.25 ml was inoculated into 25 ml of seed medium 
in a 250 ml conical flask. Flasks were incubated in a 
Gallenkamp Cooled Orbital Incubator, at 25°C, 220 r.p.m. for 
up to 3 days. Figure (2.2) shows a typical growth curve 
for the seed inoculum stage.
/ i
4.2.2 Batch Fermentation in Complex Medium,
2.5 ml of the seed culture (f^ ) / was used to inoculate 
25 ml of medium (E), ^ 10 ^, in a 250 ml conical flask. Flasks
were incubated, at 25°C, 220 r.p.m. , as for the seed culture. 
Biomass ( as g wet cell/litre ) and fermentation pH were 
recorded. Fermentation broth was analysed for biological 
activity ( see section (4.3) ). Figure (2.3) shows a typical 
growth curve.
4.2.3 Batch Fermentation in 1 Defined 1 Medium, (£3 )
S. cattleya was grown in medium (E) as indicated, after
exponential growth had ceased ( approx. 30 hours ^ 3 ) ) an<3
at subsequent stages during the fermentation, the mycelium
1 133)was washed and resuspended in medium (C), . The culture
was spun in a bench centrifuge for 5 minutes, the supernatant 
removed and an equal volume of medium (C) added, mycelium 
was gently resuspended using a glass rod and centrifuged a 
second time. The supernatant was replaced by an equal 
volume of fresh medium (C). Resuspended mycelium from all 
flasks was pooled to ensure uniformity, and finally returned 
to the incubator ( 25 ml resuspended culture/250 ml flask ), 
all procedures were carried out aseptically.
Fermentation was allowed to proceed, biomass and pH were 
recorded, broth samples were stored at -70°C prior to analysis 
for biological activity ( as were samples from (J^ ) 
fermentation ). Figure (.2.4) shows a typical growth curve.
4.3 ANALYTICAL TECHNIQUES
4.3.1 Chromat ograph i c Sy s tems
4.3.1.1 Thin Layer Chromatography
Thin layer chromatography (T.L.C.) was carried out using 
Whatman linear K silica T.L.C. plates, LK 6 DF 20 x 20 cm,
250y layer thickness. Solvent systems used were, acetonitrile: 
water 7:3, ethanol:phosphate buffer ( 10 millimolar, pH 7.0 ),
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7:3, butanol:acetic acid:water, 4:1:1. The ethanol:phosphate 
buffer system was used routinely. T.L.C. plates were run 
to completion in the solvent system and dried thorougly.
Beta lactam zones were located bioautographically using, the 
8-lactamase induction assay, the P99 inhibition assay, or 
antibacterial assays. N- Formimidoyl thienamycin was used as 
a marker.
values for 8-lactam standards in the different solvent 
systems are given in Table (3.5). T.L.C. was used to 
separate the 8-lactam components in S. cattleya fermentation 
broth, see Figures (3.13), (3.14).
4.3.1.2 High Performance Liquid Chromatography
The procedure used was a modification of that of Wilson
A Spectra-Physics Solvent Delivery System II model .
SP8 700 was used. Column effluent was monitored at 299 nm 
( carbapenems ) or 260 nm ( other 8-lactams ) , using a Pye 
Unicam LC-UV variable wavelength detector. Column dimensions 
were 4 mm I.D. x 250 mm ( pre-column 4 mm I.D. x 40 mm ) with 
packing material, Technicol LiChrosorb RP-^ g ( 10y pore size ) , 
or Spherisorb 5 ODS 1 ( 5y pore size ). Chromatography was 
performed at the ambient temperature ( approx. 22°C ), a 
500 microlitre injection loop was used. The column was eluted 
( at flow rate 1.2 ml/minute ) with 10 millimolar phosphate 
buffer, pH 7.0, tzerQ to t2Q minutes, between t2Q - t3Q 
minutes a 15% methanol gradient was added, and elution allowed 
to proceed up to t^Q minutes. Fractions were collected at 
one minute intervals and assayed for activity.
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Retention times (R^ ) for the 8-lactam standards are 
given in Table (3 .6 ). H.P.L.C. was used to resolve the
8-lactam components in S. cattleya fermentation broth,
Figures (3.17), (3.18), (3.19). Prior to H.P.L.C. fermentation 
samples were centrifuged in a Gallenkamp Minifuge for 5 
minutes at the high speed setting, or Millipore filtered 
( type HA, 0.45y pore size ) to remove particulate matter. 
Following H.P.L.C. collected fractions could be stored at 
4°C for 48 hours with no apparent loss of activity.
Wilson et al,^^^ , indicated that column performance 
deteriorated significantly with age. Therefore column 
efficiency was always checked prior to use, and the column 
head repacked as necessary.
4.3.2 Antibacterial Assays
4.3.2.1 Broth Dilution : M.I.C. Colorirnetri c Ass ay
i) Prepration of Test Organism Cultures
Broth cultures of the test organisms were prepared by 
overnight incubation at 37°C. E. coliss and C. terigena 
were grown in Nutrient Broth ( Oxoid CM 1 ), S. aureus was 
grown in Brain Heart Infusion Broth ( Gibco ) .
A viable cell count was performed by serial dilution of
the overnight cultures, in 0.85% saline, over the concentration 
— 3 — 8range 10 - 10 . 0 . 1 ml of each dilution in the series was
spread on the surface of a nutrient agar plate and incubated 
overnight at 37°C. All operations were carried out in 
duplicate. Following overnight incubation of plates, colony 
forming units per millilitre ( c.f.u./ml ) of the original 
cultures were determined.
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Prior to use in the M.I.C. assay, overnight cultures of
- 3
the test organisms were diluted to 10 in broth, incubated 
at 37°C for one hour and used immediately.
ii) M.I.C. Colorimettrc Assay
80 yl of Nutrient Broth or Brain Heart Infusion Broth
(Phenol rexl indicator 0.02% ) was added to each of the 96 wells
of a microtitre plate ( purchased from Flow Laboratories LTD ).
80 yl of the test sample added to well (A) and 2-fold serially
diluted through wells (A) to (H), twelve samples tested per
plate. 20 yl of a culture of the test organism was then
4added to each well of the plate ( approx. 10 c.f.u./well ).
The microtitre plate was sealed using acetate strip ( Flow 
Laboratories ), and incubated overnight at 37°C. In wells 
in which growth had occurred a colour change from red to 
yellow was observed, where growth was inhibited by antibiotic 
no colour change occurred, see Figure (4.1).
iii) Determination of M.I.C. of 8-lactam Standards vs. Test 
Organisms
Solutions of 8-lactam antibiotic standards, Cephamycin C, 
Penicillin N, Cephalosporin C, N-F.ormimidoyl thienamycin 
PS-5 , were prepared in 10mM phosphate buffer, at a 
concentration of 160 yg/ml. Standard solutions were filter 
sterilised using Millipore filters ( type HA, 0.45 y ).
Solutions were 2-fold serially diluted in sterile lO mM phosphate 
buffer, over the concentration range 100 - 0.313 yg/ml. Test 
solutions were used to determine the M.I.C.'s for the 8-lactam 
standards vs. the test organisms, Table (3.2).
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FIGURE (4.1)
THE M.I.C. COLORIMETRIC ASSAY
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AB AB
Samples ( H.P.L.C. fraction, antibiotic standard,
fermentation broth or phosphate buffer ) serially diluted
in broth ( + 0 .0 2 % phenol red indicator ), 20 yl overnight
4culture of test organism added ( 10 c.f.u./well ), plate 
read following overnight incubation, 37°C
(+) denotes growth of test organism ( S. aureus, C. teriqena 
E. coli SS ) phenol red indicator undergoes colour change 
red to yellow.
(-) absence of growth of test organism.
C- rows 9,10 - negative growth control i.e. no inoculation of 
test organism
C-rows 11,12 - positive growth control i.e. inoculated with 
test organism, phosphate buffer used for dilutions.
AB- antibiotic standard, e.g. NFT M.I.C. vs S. aureus = 0.0045 
yg/ml
SAMPLE (4) demonstrates antibacterial activity, growth of test 
organism inhibited wells A to F.
4.3.2.2 T.L.C. - Bioautography
Samples were separated using thin layer chromatography, 
section 4.3.1-. 1. The T.L.C. plates were then dried and 
placed in contact with agar seeded with one of the test 
organisms. Large bioassay plates ( 20 x 20 cm ) were used,
g
approximately 10 C.f.u./lOO ml, Diagnostic Sensitivity Test 
agar ( Oxoid CM 261 ) gave just confluent growth. After 
30 minutes at room temperature the T.L.C. plates were removed, 
the bioassay plates were incubated overnight at 37°C.
Bioautographic detection limit for B-lactam standards, 
determined by spotting solutions of the standards on Whatman 
No. 1 paper allowing the papers to dry and overlaying them 
on seeded agar as indicated, are shown in Table (4.1) .
4.3.3 3-Lactamase Inhibition Assay
4.3.3.1 Preparation of Nitrocefin Reagent
Fifty milligrams of Nitrocefin was dissolved in 5 ml
D.M.S.O., and made up to 120 ml with 50 mM phosphate buffer, 
as required.
4.3.3.2 Preparation of Nitrocefin Impregnated Paper
Whatman No. 1 paper was cut to size, and wetted completely 
in Nitrocefin solution ( as above ). Papers were shaken free 
of excess solution, air dried in a fume cupboard, and stored 
at -20°C. ( 100 mis of the solution was sufficient for
approximately 20 papers, 9 x 20 cm ).
4.3.3.3 Preparation of Enterobacter cloacae P 99 3-Lactamase
A strain of E. cloacae P 99+ was obtained from I.C.I. 
Pharmaceuticals, the organism was maintained on Nutrient agar 
slopes at 4°C.
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TABLE (4. 1)
BIOAUTOGRAPHIC DETECTION LIMIT FOR 6-LACTAM STANDARDS
E. COLI SS S. AUREUS C. TERIGENA
PENICILLIN N 0 . 1 0.5 1 0 . 0
CEPHAMYCIN C 0 . 1 15.0 2 . 0
CEPHALOSPORIN C 0.05 2 . 0 5.0
DEACETOXY 
CEPHALOSPORIN C 0 . 1 15.0-20.0 1 0 . 0
N-FORMIMIDOYL
THIENAMYCIN 0 . 0 2 0 . 0 0 2 0.05
MICROGRAMS (yg) ANTIBIOTIC REQUIRED TO PRODUCE AN INHIBITION 
ZONE
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E. cloacae P 99 + was used to inoculate 50 ml of Brain 
Heart Infusion broth ( Gibco ) in a 250 ml conical flask.
The culture was incubated overnight, 37°C, 180 eyeles/minute, 
in a Gallenkamp Orbital Incubator. A further 10 flasks were 
inoculated with 1 ml of the overnight culture, and shaken 
at 37°C, 180 cycles/min., for 18 hours, (1^4)^ Cells were 
harvested by centrifugation at 5500g for 15 min. ( Beckman 
J2-21, J 14 rotor 4 x 250 ml ). The cells were washed in 
100 ml 0.1 M phosphate buffer and centrifuged at 5500g for 
15 min. ( J 17 rotor 14 x 50 ml ). Following resuspension 
in 50 ml 0.1 M phosphate buffer, cells were subjected to
ultrasonic disruption to release the cell bound 6-lactamase.
TMA Sonicator Cell Disrupter ( Heat Systems Ultrasonics 
Inc ) Model W375 was used. Sonication was allowed to proceed 
for 4 minutes ( pulse 50% of cycle ), with ice/water cooling. 
Cell debris was removed by centrifugation at 17,000g for 
45 minutes, ( J 17 rotor, 14 x 50 ml ). The crude enzyme 
preparation was dialysed against 10 mM phosphate buffer 
overnight, and stored at -20°C. Enzyme activity was assayed 
using the chromogenic substrate Nitrocefin.
4.3.3.4 P 99 6“Lactaraase Inhibition Assay
i) Broth Dilution Assay
Assays were performed in microtitre plates, 8 x 12 wells 
( Flow Laboratories ). Eighty microlitres of 10 mM phosphate 
buffer was added to each well. Eighty microlitres of the 
standardised enzyme preparation was added to wells 1 - 1 2  
in row (A), the enzyme was serially diluted down rows (A) to 
(H). Twenty microlitres of standard antibiotic solution or 
test broth was added to wells (A) to (H) in line 1 of the plate, 
and so on for each sample ( 12 samples tested/plate ).
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Twenty microlitres of the Nitrocefin solution was then added 
to each well, and the plate incubated at 37°C for 15 min.
N-Formimidoyl thienamycin was used as the antibiotic 
standard ( see Figure (3.4) ), thus P99 inhibitory activity 
in fermentation broth could be estimated.
ii) T.L.C. - Bioautography
Samples were separated by T.L.C. ( section 4.3.1.1 ), the 
T.L.C. plates was dried and placed in contact with agar 
containing the P99 6-lactamase. After 30 minutes at room 
temperature, the T.L.C. plate was removed, Nitrocefin 
impregnated paper was placed on the surface of the agar. 
Following incubation at 37°C for 15 minutes, 6-lactamase 
inhibitors were visualised as yellow zones on a red background. 
Detection limit for N-Formimidoyl thienamycin was of the order 
0.05 yg.
4.3.3.5 Inhibition of P 99 6-Lactamase by 6-Lactam Standards
Solutions of the 6-lactam standards Cephamycin C, 
Penicillin N, Cephalosporin C, Deacetoxycephalosporin C, 
N-Formimidoyl thienamycin, MM 13902, MM 22383 and MM 2238 
were prepared in 10 mM phosphate buffer. The 6-lactam 
standards were tested for P99 6“lactamase inhibitory 
properties using the broth dilution assay.
4.3.4 6-Lactamase Induction Assay
A 6-lactamase induction assay ( property of I.e.I. 
Pharmaceuticals PLC. ) was used to detect 6-lactam antibiotics 
in S. cattleya fermentation broth.
4. 3..4.1 Broth Dilution Assay
Samples were serially diluted with an overnight culture
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of the test organism, there followed a period of incubation 
to allow for 3-lactamase induction. The enzyme was detected 
by addition of the Nitrocefin reagent and further incubation.
A standard solution of Ampicillin (0.02 yg/ml ) was used as 
a control, see Figure (4.2).
4.3.4.2 T.L.C. - Bioautography
Samples were separated by T.L.C., the T.L.C. plate was 
dried and placed in contact with agar seeded with test 
organism, for 30 minutes at room temperature. After removal 
of the T.L.C. plate, the agar plate was incubated to allow 
for enzyme induction. 3-Lactamase was detected ( as a red 
zone on yellow background ), by placing Nitrocefin impregnated 
paper on the agar surface and further incubation. See 
Figure (3.13).
4.3.5 Hydroxylamine Extinguishable Absorbance 299 nm
4.3.5.1 Preparation of Hydroxylamine Reagent
The hydroxylamine reagent was prepared just prior to use 
by equimolar addition of potassium hydroxide to hydroxylamine 
hydrochloride.
4.3.5.2 N-Formimidoyl thienamycin, Hydroxylamine Extinguishable 
Absorbance, 299 nm
A solution of NFT at concentration lOyg/ml in 10 mM 
phosphate buffer was prepared, and incubated with hydroxylamine, 
( final concentration in reaction mixture 8 yM/ml ), at 
room temperature for 25 minutes. Loss of absorbance at 299 nm 
was recorded, see Figure (3.6).
4.3.5.3 Effect of Hydroxylamine on 6-Lactam Standards 
Solutions of the 6-lactam standards, Cephamycin C,
(120)
FIGURE (4.2) 
g-LACTAMASE INDUCTION ASSAY
SAMPLE No .  ►
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CO f
Samples ( H.P.L.C. fraction, antibiotic standard fermentation 
broth, or phosphate buffer ) serially diluted in 
B. Iicheniformis broth culture, following incubation at 
37°C, 20 yl Nitrocefin solution added to each well, to 
detect presence of induced g-lactamase
(+) denotes presence of induced g-lactamase, Nitrocefin 
hydrolysed, colour change yellow red.
(-) no g-lactamase induction, in absence of g-lactamase 
Nitrocefin remains yellow.
Samples (9-12) Ampicillin control (0.02 yg/ml), wells
9-12 A, (-) due to antibacterial activity of Ampicilllin 
vs B . ’licheniformis
Sample (4) demonstrates g-lactamase induction, wells A-G, 
and is the major g-lactam containing fraction.
Penicillin N, N-Formimidoyl thienamycin, Cephalosporin C, 
Deacetoxy cephalosporin C were prepared at a concentration 
of 1 mg/ml ( 1 yl = 1 yg standard ).
Antibiotic standards were incubated with hydroxylamine 
( final concentration in reaction mixture 3 2 - 4  yM/ml ), 
for 25 minutes at room temperature. 1 yl of the reaction 
mixture was spotted onto Whatman No. 1 paper, after drying 
the papers were overlayed on seeded agar plates for 30 minutes 
at room temperature. The plates were incubated at 37°C 
overnight, E. coliss was used as the test organism, ( 100 ml 
D.S.T. agar seeded with 0.1 ml of an overnight culture ), 
see Table (3.3).
4.3.5.4 Differential Spectrophotometry
Difference spectra were obtained using a Pye-Unicam SP8- 
100 Ultraviolet Spectrophotometer, in the scanning mode.
Reacted and unreacted samples were scanned in the region
401.5 ^ 187 nm. Bandwidth was set at 2 nm, with a wavelength 
speed of 1 nm/cm. See Figure (3.7)
4-3.6. Deacyiation of PS-5
Acylase 1( N-acylamino acid amido hydrolase E.C. 3.5.1.14 ) 
was purchased from Sigma Chemical Company. One unit of 
activity hydrolysed 1 yM of N-acetylmethionine per hour, pH 
7.0, 25°C.
The enzyme was prepared over the concentration range 
2 - 3 2  mg/ml in lOmM phosphate buffer pH 7.0 ( 1 mg solids 
contained 1805 units of enzyme activity ). PS-5 was used at 
a concentration of 20 yg/ml. Ninety microlitres of the 
antibiotic solution was incubated with 10 yl of enzyme solution 
for up to 4 hours at 37°C, samples were taken at half hourly
(122)
intervals. Samples were loaded on Whatman LK 6DF chromatography 
plates, 20 yl loaded/track. T.L.C. plates were run in the 
solvent system, ethanol:phosphate buffer, 10 mM pH 7.0, 7:3, 
for 3 hours and air dried. Deacylation of PS-5 was detected
using the g-lactamase induction assay. Acylase 1 was
2+ 2 -5' activated 1 by Co over the range 1 x 10 - 1 x 10 M,
for optimal deacylation of PS-5, the acylase was used at a
2+ -4concentration of 32 mg/ml, Co 1 x 10 M,and incubation at 
37°C for 2 hours, see Figure (3 .8 ).
4.3.7 Susceptibility of Carbapenems to Renal Dipeptidase
4.3.7.1 Preparation of Dipeptidase from Pig Kidney
The method used was a modification of that of B. J.
Campbell and is summarised in Figure (4.3 ).
Dipeptidase activity was increased by addition of ZnSO^.
7H2O to the enzyme preparation, to a final concentration of
3 mM. ' Activation " was allowed to proceed overnight at 4°C,
2+and the enzyme used within 3 days. Addition of Zn 
permitted a reduction of the incubation period from 3 hours 
to 30 minutes. Enzyme activity was diluted to obtain a 
standard preparation, which under the incubation conditions 
used ( see below ) gave a reduction of 8 to zero wells in 
the g-lactamase induction assay, with the NFT standard.
4.3.7.2 Effect of Renal Dipeptidase on g-Lactam Standards
Solutions of the g-lactam standards Cephamycin C, 
Penicillin N, N-Formimdoyl thienamycin, Cephalosporin C, 
Deacetoxy cephalosporin c  , in 10 mM phosphate buffer were 
made at concentrations of 50, 25, and 10.yg/ml. One hundred 
and sixty microlitres of the g-lactam solution was incubated 
with forty microlites of Dipeptidase or phosphate buffer for
FIGURE (4. 3)
SUMMARY OF PREPARATION OF DIPEPTIDASE FROM PIG KIDNEY, * 175)
Fresh pig kidney, 2 Kg, (skin, fat and 
medulla removed), homogenised with 
2 litres of iced water
pellet discarded
pellet discarded
centrifuged, 1300g, 20 min
supernatant adjusted to pH 5, 1 M HCl
centrifuged, 1300g, 20 min
pellet retained
supernatant adjusted to 2 0% saturation 
(NH4 )2S04, left 1 hour, 0°C.
centrifuged, 1300g, 20 min
pellet retained
supernatant adjusted to 30% saturation 
(NH4)2S04, 1 hour, 0 °C.
centrifuged, 1300g, 20 min.
pellet retained
continued as above to 60% saturation
(nh4 )2so4
pellets and supernatant assayed for activity 
vs glycyldehydrophenyl alanine by following 
loss of absorbance, 275 nm.
Dipeptidase activity located in 40% pellet, crude Dipeptidase 
was stored in aliquots at -70°C.
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30 minutes at 37°C. Twenty microlitres of incubation mixture 
was loaded on Whatman Antibiotic Assay discs, ( 6.35 mm 
diameter ). Assay discs were dried and placed on seeded agar 
( E. coliSS, 0.1 ml overnight culture to 100 ml D.S.T. agar ). 
After a 30 minute period at room temperature ( prediffusion ) 
seeded plates were incubated overnight at 37°C, see Table (3.4). 
N-Formimidoyl thienamycin was found to be appreciably more 
sensitive to hydrolysis by Dipeptiadase than other g-lactam 
standards, under these conditions.
4.3.7.3 Relative Susceptibility of g-Lactams Co-produced in 
S. cattleya Fermentation Broth, to Renal Dipeptidase 
(DHP)
A sample of S. cattleya fermentation broth, medium (E)
94 hours (f2) , was separated using H.P.L.C., fractions 1 - 60 
were collected and assayed for g-lactamase induction activity 
and antibacterial activity vs. S. aureus. Figure (3.10).
Peak fractions were labellled I to V with corresponding 
retention times 5/7, 13, 3 3, 36 and 41 minutes.
Susceptibility of fractions I to V to the Dipeptidase 
was determined using the g-lactamase induction assay. N-Form­
imidoyl thienamycin and PS-5 were used as standards. Sixty 
four microlitres of the sample ( H.P.L.C. fraction or 
antibiotic standard ) was incubated with 16 yl DHP, a control 
was included in which DHP was replaced by 10 mM phosphate 
buffer . Incubation was carried out at 37°C, 0 - 3 0  minutes / 
in microtitre plates, the induction assay was then carried 
out as previously described. Reduction in the ability to 
induce g-lactamase formation ( expressed as % t = 0 ) was 
plotted against incubation time for fractions I to V and for 
NFT and PS-5, see Figure (3.11).
(125)
CHAPTER FIVE 
DISCUSSION
5.1 INTRODUCTION
Chapter five reviews the results of our studies with 
S. cattleya, and presents an outline of current understanding 
of the biosynthesis of carbapenems in Streptomyces sp., with 
particular attention to the. production of Thienamycin by 
S. cattleya. Recent developments in the field of biosynthesis, 
such as the use of genetic engineering and protoplast fusion 
techniques, are also discussed.
Thienamycin is of considerable importance as a chemother­
apeutic agent, in spite of its superior properties Thienamycin 
( or the N-formimidoyl derivative NFT ) may be subject to 
problems associated with the clinical use of 3-lactam 
antibiotics. NFT was found to be capable of, inducing 
g-lactamase formation in clinical isolates, which could then
interfere with activity of the a n t i b i o t i c , . clinical
(177)strains of Bacteroides fragelis, and Pseudomonas
/1 7 o\
maltophilia, , have been shown to produce g-lactamase
which can hydrolyse NFT. Preincubation of Methicillin 
resistant Staphylocoecus aureus ( M.R.S.A. ) , clinical isolates 
with sub-inhibitory concentrations of NFT resulted in
( 179)markedly increased M.I.C.'s for both Methicillin and NFT, ,
a phenomenon thought to be due to induction of an altered 
penicillin binding protein, P.B.P.2', rather than g-lactamase 
induction/180} .
Emergence of resistant organisms emphasises the continuing 
need for new and novel g-lactam antibiotics, together with 
novel strategies for administration of already known g-lactams. 
Synthetic schemes for modification of the carbapenem nucleus,
have been designed and may provide altered carbapenem 
structures of clinical significance, 182) increased
knowledge of the biosynthetic pathway and its control, may 
lead to discovery of new carbapenems via ' directed biosynthesis'.
5.2 PRODUCTION OF THIENAMYCIN AND RELATED CARBAPENEMS BY
S. CATTLEYA
Chapters two and three present the results of studies 
on the production of Thienamycin and related carbapenems by 
S. cattleya. Fermentation was carried out in both complex 
and defined medium. The major g-lactam product, of 
fermentation, was identified as Thienamycin. Although progress 
of the work was impeded by, problems of culture maintenance, 
and a significant degree of variability in growth of the 
organism and in antibiotic production, it may be possible 
to draw some general conclusions.
A batch fermentation system, as used here, presents a
poorly defined system for investigation of the parameters
controlling antibiotic formation. The organism is constantly
adapting to a new environment, thus a steady state may never
be achieved. With continuous culture a steady state could be
maintained, and individual variables studied more rationally.
Distinction between growth rate effects and effects due to
specific substrates / ^ 8 \  may then have been possible. Use
of washed cells may have permitted description of certain
(183)
features at the enzyme level, . A particular pattern of
primary metabolic enzymes ( e.g. enzymes of nitrogen 
assimilation ) may be conducive to antibiotic production. 
Manipulation of growth conditions could allow imposition of 
this desirable pattern of enzymes in the cell.
(12 8)
Several analytical techniques for the identification of 
carbapenems in S. cattleya fermentation broth have been 
evaluated. The major g-lactam product behaved in a manner 
consistent with it being Thienamycin. Other minor g-lactam 
products were also detected, but have not been satisfactorily 
identified. Their behaviour in a number of assays suggested 
they were carbapenem in nature, ( see chapter three ).
Further identification of these minor broth components will 
necessitate their isolation and purification, with subsequent 
chemical analysis t an approach that would require large scale 
fermentation, due to the low fermentation productivity and
u • i ■ 4- 1..T4- * 4-u 4. (160,161,162)chemical instability of these components,
Although in this instance isolation and purification of 
fermentation products was not achieved, feeding studies using 
radiolabelled precursors and application of autoradiographic 
techniques, may have yielded interesting results without the 
need for purification. However time limitations prevented 
our work in this area from proceeding beyond a very preliminary 
stage.
5.3 BIOSYNTHESIS OF CARBAPENEMS
Present knowledge of the biosynthetic pathway leading to 
the carbapenem class of g-lactams is very sparse and 
fragmentary. Limited studies involving administration of 
isotopically labelled likely precursors, and the use of 
blocked mutants, have allowed speculation as to the nature of 
the biosynthetic sequence/80 .^ An overview of currently available 
information is given here. Figure (1.3) shows the chemical 
structures of carbapenems. ( See page 12 ).
(129)
5.3.1 Studies using Isotopically Labelled Precursors
5.3.1.1 Origin of the Five-Membered Ring of Thienamycin
Preliminary studies suggested that glutamic acid was
the precursor of the five-membered ring of Thienamycin, and
(119)
that the glutamate molecule was incorporated intact, ,
see Figure (5.1). An observation that allowed comparison
with the origin of the five-membered ring of Clavulanic acid,
also thought to be derived from glutamate, ( 96 )  ^ Recent
studies however suggest that ornithine is in fact the precusor
(117)
of Clavulanic acid, , see Figure (1.8 ).
5.3.1.2 Origin of ^^  and C ^ 7  ^ g-Lactam Carbons
Investigations by workers at Merck indicated that acetate
was efficiently incorporated into Thienamycin by S. cattleya,
(119) Feeding experiments with (1,2-^C) and (2-^C)
acetate demonstrated incorporation of intact acetate units
(136)
predominantly in C ^ - C ^ ,  . An acetate unit was also
incorporated to a lesser extent at C ^ - C ^ ,  which could be
13 13explained as (1,2- C) labelled acetate yields (4,5- C)
glutamate via the tricarboxylic acid cycle (TCA), which in
13turn gives Thienamycin enriched for ( C) at C (4)~C(5 )' 
see Figure (5.2).
5.3.1.3 Origin of the C Hydroxyethyl Side Chain
The possibility that the hydroxyethyl side chain of
Thienamycin could be formed by two single carbon transfers
has been i n v e s t i g a t e d / . l- (methyl ^c) methionine was
very efficiently utilised in biosynthesis of the antibiotic by
13S. cattleya. Experiments with L- (methyl c) methionine
13revealed a high degree of incorporation of ( c) at C^gj and
(130)
PRELIMINARY STUDIES OF THIENAMYCIN BIOSYNTHESIS USING
RADIOLABELLED PRECURSORS, ORIGIN OF THE CARBON SKELETON, (119*
2
I) Incorporation of deuterium from L-(2,4,4, H^ ) glutamic acid
co2h
S. cattleya
OH
NH
glutamic acid
2
(4, H,)Thienamycin
13 13II) Incorporation of C from Cy-cark°xyl C) glutamic acid
S. cattleya
OH
L-(5, c) glutamic acid
COoH
+
•co2
13(5, C)Thienamycin
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FIGURE (5.2)
INCORPORATION OF (1/213C) ACETATE INTO THIENAMYCIN,(119)
co2h
/Y\. ,  ^ S. cattleya 
<  i \ --------
OH
(1,2 C)acetate
13(6,7 C)Thienamycin
(p re domin an t ly)
CO,H CO,H
TCA
H,/C\X H
■H
H
H
H
13(1,2 C)acetate
U-'l-
u N C 0 2 h
13.(4,5 C)glutamate 
\
13(4,5 C)Thienamycin
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C (9) ' with no apparent incorporation at any other site. The
hydroxymethyl side chain of Northienamycin was also found
14to have methionine as its precursor. ( C ) formate was 
very poorly incorporated into the side chain probably
due to the high level of formate dehydrogenase in S. cattleya 
(136)  ^ Formation of an ethyl group from two methyl groups has 
already been documented with respect to the C(2 4) ethyl group 
of certain plant sterols, 1^39)^
5.3.1.4. Origin of the C ^| Side Chain
14 35Experiments were carried out with ( C) or ( S)
35cystine, and ( S) pantethine to determine the likely 
precursor of the C(3 j side chain of Thienamycin, ( S. cattleya 
possesses enzymes capable of reducing a number of disulphide 
compounds to their sulphydryl form ) , .
L-fU- C) and ( s) cystine were very efficiently
incorporated into the Thienamycin molecule, radioactivity
being located in the side chain. Molar specific
incorporations in excess of 70% of the theoretical maximum
35were observed. In contrast ( s) pantethine was very poorly 
incorporated, . Williamson et aJL favour a direct role
for cysteine in the formation of the cysteaminyl side chain of 
Thienamycin, .
3 35Studies with ( H) & ( s) cystine demonstrated that the
cysteaminyl side chain was not unsaturated during its synthesis.
3 35The Thienamycin synthesised was found to have the same H/ S 
ratio as the starting material t ruling out the possibility 
of a dehydrothienamycin species as a direct precursor of 
Thienamycin. Cysteine appeared to be decarboxylated after 
addition to the antibiotic nucleus as cysteamine itself 
was poorly incorporated into Thienamycin, (-136).
5.3.2 Studies using Blocked Mutants
5.3.2.1 The OA-6129 Carbapenems
Following discovery of the OA-6129 group of 
carbapenems, (184)^ their structure elucidation, ,
OA-6129 carbapenems were distinguishable from other 3-lactams 
by possession of a pantothienyl side chain, see Figure
(1.3). Speculation ensued as to their biosynthetic 
relationship with other carbapenem groups.
A mutant of Streptomyces fulvoviridis A933 17M9, was
isolated, and found to produce, OA 6129A, OA 6129B^,
OA6129B2f and OA 6129C, instead of PS-5, Epithienamycins
(19)A and C, and MM 17880 respectively, , see Figure (1.2) J
demonstrating that carbapenems with pantothienyl side
chain may act as direct biosynthetic precursors for at least 
some carbapenems.
Subsequent studies, (^85,,186,187) ^ revealed that the mutant 
lacked depantothenylating activity found in the parent strain 
and designated as A933 acylase. Similar enzyme activities 
have been found in other Streptomyces sp that produce 
carbapenems, including S. cattleya, . Figure (5.3).
5.3.2.2 S. cattleya Blocked Mutants
Rosi et. al isolated two S. cattleya mutants that were
a l t e r e d  in carbapenem biosynthesis. One produced an
N-Acetylthienamycin, and the other a deshydroxy analogue
(14)of Thienamycin corresponding to NS-5, , see Figure (1.3).
Williamson et ad., t concluded that the addition of
the hydroxyl group is one of the terminal steps in the
biosynthetic pathway. Whether the oxygen originates from O2 
or H2O has yet to be determined. The dehydroxy analogue
(134)
FIGURE (5.3) -
(A) DEPANTOTHENYLATION OF OA 6129 CARBAPENEMS BY A933 ACYLASE (185)
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H H3c CH3
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(B) ACYL EXCHANGE BETWEEN OA 6129 CARBAPENEMS AND ACYL CoA1 s
BY A9 33 ACYLASE, (185)
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( R = -CH(CH3)OH
-CH(CH3 )0S03H or
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of Rosi et al may in fact be the biosynthetic precursor of 
Thienamycin itself. Addition of a hydroxyl group to the 
prochiral centre of may account for the small amount
of 8-Epithienamycin produced by S. cattleya, if the reaction 
involved is not absolutely stereospecific.
5.3.2.3 Streptomyces griseus Blocked Mutants
Nozaki et al isolated three types of blocked mutant from
S. griseus subsp. cryophilus, which appeared to be impaired
(24)in specific steps of carbapenem biosynthesis, . A
biosynthetic pathway for the terminal stages of formation of 
5,6-cis carbapenems was proposed, see Figures (5.4) and (5.5).
The cysteaminyl side chain of Thienamycin does not appear 
to be unsaturated during its synthesis, . a dehydro-
thienamycin species as a precursor of Thienamycin therefore 
seems extremely unlikely. N-Acetylthienamycin and N-Acetyl 
dehydrothienamycin are possibly produced by S. cattleya as 
shunt metabolites, by a divergent branch in the biosynthetic 
pathway. A pathway similar to that of S. griseus may 
operate in the dehyrogenation of N-Acetylthienamycin to give 
N-Acetyldehydrothienamycin.
5.3.3 Studies using Metabolic Inhibitors
5.3.3.1 Inhibition Of Thienamycin and Cephamycin C 
Synthesis in S. cattleya
The biosynthetic relationship between Thienamycin, and 
Cephamycin C, was probed by Williamson et al, by manipulation 
of the growth conditions, and the use of selective metabolic 
inhibitors ,  ^  ^.
Thienamycin synthesis alone could be substantially
2 +reduced by elimination of Co from the growth medium.
(136)
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PRODUCED BY S. GRISEUS, (24) 
(. see also Figure (5.4)
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Thiaisoleucine ( a sulphur analogue of isoleucine ) was 
found to inhibit Thienamycin but not Cephamycin C synthesis, by 
an unknown mechanism. Isoleucine may provide acetate units 
for Thienamycin biosynthesis, and may explain the stimulatory 
effect of branched chain amino acids on synthesis, .
Conversely an analogue of lysine, aminohydroxy caproic acid, 
was found to inhibit Cephamycin C synthesis but not 
Thienamycin synthesis, possibly by blocking conversion of 
lysine to a-aminoadipic acid, .
Thus it would appear that Thienamycin and Cephamycin C 
are formed by independent biosynthetic pathways, although 
they share the common precursors cysteine and methionine. 
Conceivably the biosynthetic pathways could also involve 
common enzymes.
5.3.3.2 Reverse Transsulphuration in S. cattleya
Reverse t ran s sulphur at ion describes the reactions by
which the sulphur atom of homocysteine and the carbon chain
of serine are combined to form cysteine, see Figure (5.6).
Clearly cystathionine y lyase is a key enzyme in the pathway.
Williamson et al suggest that reverse transsulphuration is
a general feature of sulphur metabolism in Actinomycetes,
(189)
Studies have shown that cystathionine, methionine, and 
cysteine are all efficiently utilised by S. cattleya for 
antibiotic synthesis, . a mechanism based inhibitor
of cystathionine y lyase, propargylglycine, was found to 
inhibit the synthesis of both Thienamycin and Cephamycin C 
in S. cattleya, . Inhibition was reversed by providing
the cells with another source of cysteine, such as cystine,
(139)
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which would suggest that reverse transsulphuration is a 
major pathway used to provide cysteine in S. cattleya, .
The ability of methionine to reverse the effects of 
propargylglycine inhibition, may be explained if the addition 
of methionine to the culture spares the small endogenous 
pool of cysteine for antibiotic synthesis, . Assuming
cysteine sulphur can be converted to methionine sulphur via 
direct transsulphuration in S. cattleya. Evidence suggests
that direct transsulphuration does occur in other
04- 4. (190)Streptomyces sp.,
5.3.4 Hypothetical Scheme for Biosynthesis of Thienamycin
A hypothetical scheme for the biosynthesis of Thienamycin 
and other carbapenems has been proposed by Williamson et al, 
(136) ^ based on their own studies, and data currently 
available in the literature, see Figure (5.7). The 
difficulty arises in reconciling information often of a 
fragmentary or contradictory nature, into a single biosyntheti 
pathway, given the diversity of carbapenem structures. The 
scheme proposed by Williamson et al involves cyclisation 
of the five member and four member rings to form the 
carbapenem nucleus, with subsequent addition of 
(Cg) substituents.
In carbapenem biosynthesis we may be dealing with a 
multiply branched pathway, involving a common biosynthetic 
stem, a complex array of possible terminal pathways may 
exist. The type and proportion of different carbapenems 
produced could be determined by such factors as :
1) Streptomyces species ( or Bacterial species ).
2) Growth conditions, for example the amount of free sulphate
THIENAMYCIN AND OTHER CARBAPENEMS, (136)
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in the case of sulphated/nonsulphated carbapenems.
3) Enzymes produced, for example acylase activity, 
depantothenylating activity .
4) Amount and.type of acyl-CoA's available for acyl exchange.
The carbapenem nucleus gives wide scope for chemical 
modification, (-181,182)^  ^  hardly surprising that this also 
appears to be the case for microbial modification. As 
indicated by Williamson, , areas that require further
investigation are, the origin of the C^gj hydroxyl group 
of carbapenems, and whether the isotope labelling studies 
used in determining the origin of the carbon skeleton of 
Thienamycin hold true for other carbapenem producers. An 
important investigative tool is likely to be the use of 
advanced intermediates as precursors in cell free systems/ 
extracts.
5.4 THE ROLE OF PANTETHIENE IN CARBAPENEM BIOSYNTHESIS
Discovery of the OA 6129 carbapenems, t led to
speculation about the involvement to pantethiene in the 
biosynthesis of carbapenems. Several possible roles for
/ I QT\
pantethiene have been proposed, . Firstly the
pantethiene could act as a precursor for the pant-
othienyl side chain. Secondly Coenzyme A ( with a 
pantothienyl moiety as acyl carrier ), could be involved 
in cell growth, and also in the derivation of the 
acetylaminoethylthio side chain of some carbapenems, by an 
acyl exchange reaction. And finally that a thiotemplate 
system of peptide antibiotics, ( ^ 1 )^  might operate in the 
biosynthesis of carbapenems.
That structures possessing a-C^j pantothienyl side
chain, could act as intermediates in biosynthesis of certain
carbapenems, was demonstrated in Streptomyces fluvoviridis,
(19) Whether this applies to carbapenem biosynthesis 
generally, is not yet clear. In S. fulvoviridis a specific 
acylase catalyses the depantothenylation of OA 6129 
carbapenems,  ^ The enzyme also catalyses acyl exchange,
of the side chain of OA 6129 carbapenems, with acyl
CoA's, see Figure (5.3). Similar enzyme activities have 
been determined in other carbapenem producing Streptomyces, 
including S. cattleya, .
To date, pantothienyl intermediates have not been
detected in S. cattleya fermentations. Incorporation of
35 35( S) labelled cysteine, and ( S) pantethiene, ( at a level
3574 times lower than that of ( S) cysteine ) into the 
side chain of Thienamycin have been reported, . As
S. cattleya is able to utilise exogenous pantethiene, 
it would appear that the preferred precursor of the 
side chain in S. cattleya is in fact cysteine. Radiolabelled 
pantothenate was not taken up into the mycelium of 
S. fulvoviridis, however radiolabelled 3-alanine was specific­
ally incorporated into the 3-alanyl portion of the C (^3)
(1 8 7)
pantothienyl side chain of OA 6129 carbapenems,
The thiotemplate system described by Lipmann, (^1) ^ 
involves a pantethiene moiety, within a multienzyme unit 
which functions as a carrier arm for peptide elongation.
Such a system could operate in carbapenem biosynthesis, 
subsequent cyclisation of the peptide giving rise to the 
carbapenem nucleus. Although judging from the structure 
of the OA 6129 carbapenems, one molecule of pantethiene
appears to be consumed in producing one molecule of the 
antibiotic , (1 ^6 )  ^ incorporation of an intact glutamate 
unit into the five-membered ring of Thienamycin by 
S. cattleya, (H9) wou^(j seem to be incompatible with
thiotemplate peptide synthesis, and subsequent cyclisation 
of Thienamycin.
The role of pantethiene in carbapenem biosynthesis, and 
the origin of the C^j side chain of carbapenems are open to 
question. A number of potential precursors may exist, that 
are preferentially used by different Streptomyces sp. 
depending on the metabolic pool, to provide the side
chain. This in itself points away from thiotemplate 
synthesis, in which pantethiene would play a very central 
role in biosynthesis.
5.5 THE ROLE OF COBALT IN CARBAPENEM BIOSYNTHESIS
The role that cobalt fulfills in carbapenem biosynthesis
is not yet understood. A number of possibilities are
presented and discussed in greater detail in chapter two,
including, regulation of biosynthesis, or activity of, the
antibiotic synthetases, formation and correct functioning
of vitamin and regulation of glutamine synthetase
activity. To date the studies carried out consist largely 
2 +of adding Co or vitamin B ^  bo the fermentation and noting 
the effect on antibiotic production.
Trace metals can greatly influence secondary metabolism,
and often have an important role to play, . At present
the effect of manganese on patulin production in Penicillilium
urticae is probably the most well characterised system, for
the involvement of a metal ion, in this case in fungal
/192)secondary metabolism, . These studies present a
detailed investigation of the essential role of manganese, and 
indicate a growing awareness of the significance of metal 
ions in antibiotic biosynthesis.
An insight into the site and mode of action of metal 
ions in secondary metabolism will influence our ability to 
manipulate organisms and their biosynthetic pathways to 
enhance the formation of desirable products. It may be 
possible to remove a ' key ' metal ion from its functional 
site using highly selective chelating agents, demonstrating 
very strong affinity for single metal. Conceivably a 
natural product could fulfill this requirement, presently 
available chelating agents may not be sufficiently specific 
for individual trace metals.
The cyclopentenedione antibiotic ( a cobalt chelator ), 
produced by S. Cattleya, f could be involved in the
control of secondary metabolism in this organism. For 
example the cyclopentenedione may sequester available cobalt, 
and thereby prevent activation of preformed enzymes until 
after the growth phase, thus delaying the onset of antibiotic 
biosynthesis. However the precise role(s) of cobalt ( and 
the cyclopentenedione ) remain to be determined.
5.6 FUTURE PROSPECTS
The biosynthetic pathway leading to penicillin, 
cephalosporin and cephamycin 3-lactams is reasonably well 
established, ( see chapter one ), and at least partially 
elucidated at the enzyme level, (96'105'1097193'194).
Attention is now being given to the mechanism by which 
individual enzyme reactions occur, . Biosynthetic
pathways for recently discovered 3-lactam classes are
(147)
currently under investigation. It is recognised that a 
number of regulatory controls may influence secondary
/ Q ^2 ^ j
metabolism, ' . Largely, the actual regulatory
mechanisms remain obscure, as does the underlying genetic 
determination of secondary metabolism. Knowledge of the 
gene-enzyme relationships involved in antibiotic synthesis 
is extremely scanty, (148)^
Factors contributing to the lack of progress, in under­
standing of some aspects of secondary metabolism and anti­
biotic biosynthesis, may have included :
1) The success of industrial strain development programs to 
furnish mutants with increased production ability, using 
the traditional random mutation and screening approach.
2) The considerable empirical knowhow, that existed, of the 
nutritional and environmental factors affecting 
antibiotic production, .
Thereby obviating the need for comprehensive understanding 
of antibiotic biosynthetic pathways and their control.
However there are indications that developments in fundamental 
biochemistry and genetics will provide a sound basis for 
research into the genetics and molecular biology of anti­
biotic biosynthesis. Further knowledge will be necessary to 
fully exploit some of the new techniques available. Genetic 
engineering, and protoplast fusion techniques are likely to 
be of considerable importance to the future of antibiotic 
research.
Conditions for the formation and reversion of 
Streptomycete protoplasts were originally developed by 
Okanishi et a l ,  # More, recently the technique has
(148)
(19 7been applied to antibiotic producing Streptomycetes, '
19 8,199)  ^ Protoplast fusion techniques permit intra and
inter species recombination, to improve antibiotic
• (190) n (200)yields, , or provide novel antibiotics,
Protoplasting and regeneration may result in increased
antibiotic yield, (201) r or in plasmid 1 curing '. Protoplast
techniques have an extensive role to play in the genetic
analysis of antibiotic biosynthesis, (H2)^ see Table (5.1).
As cloning vectors are increasingly available for 
Streptomyces sp., recombinant DNA techniques should prove 
very useful in the genetic analysis of antibiotic biosynthesis, 
(107,H4) # Recently the S. ciavuligerus genes, for 
Clavulanic acid biosynthesis have been cloned, .
Ultimately genetic manipulation of the biosynthetic 
pathways, of antibiotic producing organisms should be 
achievable. For example, increases in antibiotic yield by 
the use of multicopy genes, or transfer of the ability to 
make an antibiotic from an organism with less desirable 
characteristics, to one more amenable to economic industrial 
fermentation.
Increased knowledge of biosynthetic pathways, and the
individual enzyme reactions involved, together with an
understanding of the regulatory mechanisms' controlling
antibiotic biosynthesis, will allow a more direct approach to
the design/manipulation of producing organisms. Bottlenecks
in the biosynthetic pathway could be removed by deregulation
(122)of the rate limiting step, . Advanced intermediates
could be designed in the form of modified substrates i.e., 
structural analogues, which could lead to formation of 
novel products, (110,202,203,204)^ Current immobilised
(149)
TABLE (5.1)
THE ROLE OF PROTOPLAST TECHNIQUES IN GENETIC ANALYSIS,(112^
1) Generalised recombination through protoplast fusion.
2) Plasmid " Curing " by protoplasting and regeneration.
3) Transformation/transfection of protoplasts by plasmid 
or 1 phage ' DNA.
4) Gene cloning on plasmid or 1 phage 1 vectors.
5) Transformation of protoplasts by chromosomal DNA 
entrapped in Liposomes.
6 ) Artifical feeding of metabolic precursors using 
Liposomes.
(150)
, (205,206,207) , . .enzyme methology, ' ' and protein engineering
techniques, may have a significant role to play, in
that use of substrate analogues or altered enzymes could
give rise to novel 3-lactam structures, . The
rational/semirational design of antibiotic producing strains,
with increased antibiotic yields, novel antibiotic products,
or other desirable properties may be feasible. In conclusion
we are moving into an exciting period in antibiotic
research in which a detailed understanding of biosynthesis
and its regulation is no longer of purely academic interest.
(151)
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APPENDIX A 
Media Recipes
1) Seed (inoculum) Medium
% g/1
Glycerol 3.0 30.0
Peptone (Oxoid L37) 2.0 20.0.
CaC03 0.1 1.0
KH2P04 0.024 0.24
MgS04.7H20 0.02 0.20
M.E.C. 0.01 1 ml
Minor Element Concentrate (M.E.C.)
Ferrous sulphate.7H20 0.1
g/i
1.0
Cupric sulphate.5H20 0.015 0.15
Zinc sulphate.7H20 0.1 1.0
Manganese sulphate.4H20 0.01 0.1
Potassium molybdate 0.01 0.1
Acidify to obtain a clear solution, add to media (v/v)%
2) Medium (E) , Kahan et al ^ 1°^
g/i
Glucose 25.0
Corn steep liquor 15.0
Peptone (Oxoid L37) 10.0
Cotton seed medium 5.0
CoC12 .2H20 lOmg
Adjusted to pH 7.3 with NaOH 
CaC03 3.0
Corn steep liquor (C.P.C. Corn Products Ltd) and cotton seed 
media (Milou-Pro) were obtained from ICI Pharmaceuticals PLC.
(168)
APPENDIX A CONTINUED
Corn steep liquor stored at 4°C.
(133)3) Medium (C), Aharonowitz and Demain,
g/1
Glycerol 10.0
L-asparagine 2.0
MgSO^ (anhydrous) 0.6
K2HP04 1.0 ( 6mM )
Morpholinepropane sulphonic acid 20.93 ( 100 mM )
(MOPS)
CoC12 .2H20 lOmg
Trace salts solution 1 ml
Adjusted to pH 6 . 8 with NaOH
Trace salt solution g/1
FeSO..7Ho0 1.04 2
MnCl2 .4H20 1.0
CaCl2 .2H20 1.0
Media autoclaved 20 minutes 121°C and used within 3 days.
